{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# install dependancies\n",
    "# !pip install langchain openai pypdf tiktoken chromadb\n",
    "# !pip freeze > requirements.txt "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n",
      "                                 Dload  Upload   Total   Spent    Left  Speed\n",
      "100  264k  100  264k    0     0   585k      0 --:--:-- --:--:-- --:--:--  584k\n"
     ]
    }
   ],
   "source": [
    "# !curl -o mm_htn_guidelines.pdf \"https://pstat-live-media.s3.amazonaws.com/pdf_cache/policy/8093105/f867219b-a6bd-40a1-a8ec-ebfdbb3d8adc/Ambulatory%20Adult%20Hypertension%20Guideline.pdf\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "FILE_PATH = \"./mm_htn_guidelines.pdf\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Environment variables loaded successfully!\n"
     ]
    }
   ],
   "source": [
    "from dotenv import load_dotenv, find_dotenv\n",
    "# import os\n",
    "\n",
    "if load_dotenv(find_dotenv()):\n",
    "    print(\"Environment variables loaded successfully!\") \n",
    "    # print(os.getenv('OPENAI_API_KEY'))\n",
    "else:\n",
    "    print(\"Could not load environment variables.\") "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# document Loader\n",
    "from langchain.document_loaders import PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "import tiktoken\n",
    "\n",
    "tokenizer = tiktoken.get_encoding('cl100k_base')\n",
    "\n",
    "def tiktoken_len(text):\n",
    "    tokens = tokenizer.encode(text, disallowed_special=())\n",
    "    return len(tokens)\n",
    "\n",
    "pdf_loader = PyPDFLoader(FILE_PATH)\n",
    "\n",
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=1000,\n",
    "    chunk_overlap=200,\n",
    "    length_function=tiktoken_len,\n",
    "    separators=[\"\\n\\n\", \"\\n\", \" \", \"\"]\n",
    ")\n",
    "\n",
    "pdf_data = pdf_loader.load() #load_and_split(text_splitter=text_splitter)  # can use this instead of .load() and then no need for below line\n",
    "documents = text_splitter.split_documents(pdf_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='COPYStatus Activ e PolicyStat ID 8093105 \\nOrigination 02/1997 \\nEffectiv e 08/2021 \\nLast Re vised 08/2021 Area Ambulat ory \\nPatient Car e \\nApplicability UMHS-Clinical \\nPublic \\nReferences Guideline \\nAmbulat ory Adult Hyper tension Guideline \\nPatient population: \\nObjectiv es: \\nKey aspects and r ecommendations: \\n• Diagnosis \\n◦ Although a single, car efully tak en blood pr essur e (BP) r eading ma y predict futur e \\ncardiovascular risk, for clinical purposes this risk is better identified b y taking the \\nmean BP le vel from r ecor dings o ver se veral visits. \\n◦ Home and ambulat ory blood pr essur e monit oring helps impr ove BP contr ol, and \\nidentifies \" white coat\" and \" mask ed\" hyper tension [IIA]*. \\n◦ If home BP monit oring is used, car eful calibr ation of the BP monit or and thor ough \\npatient education ar e essential. \\n◦ Individuals with mean BP > 135/80 should be scr eened for diabetes [IB]. \\n• Treatment \\n◦ For patients without diabetes or end or gan damage, target of BP for \\n▪ Age < 60 y ears is < 140/90 mm Hg  [IA]. \\n▪ Age ≥ 60 y ears is <150/90 mmHg [IB]. \\n◦ For patients with diabetes or end or gan damage (e.g. r enal insufficiency , retinopathy , \\nCHF, CAD , PVOD, cerebrovascular disease), appr opriate tr eatment of hyper tension Adults age 18 and older . \\n(1) Accur ately diagnose hyper tension. (2) Impr ove blood pr essur e (BP) contr ol. (3) Decr ease \\nhyper tension-r elated morbidity and mor tality (4) Encour age patient’ s self-inv olvement. (5) Pr ovide \\nappr opriate education and follow-up. (6) Pr ovide cost-eff ectiv e car e. \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 1 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 0}),\n",
       " Document(page_content='COPY(HTN) pr ovides significant impr ovements in clinical outcomes  [IA]. Recommended BP \\ntargets ar e syst olic blood pr essur e of < 140 mmHg ( [IB] for CHF and CAD; [ID] for \\ndiabetes and other end or gan damage)  and diast olic BP goal of < 90 mmHg [IB]. \\n◦ Treatment of SBP o ver 160 mmHg is impor tant in r educing CV A and CHF risk [IA]. \\n◦ Lifestyle modifications t o lower BP ar e impor tant adjuncts t o drug ther apy [IA]. \\n◦ Begin ther apy with a thiazide diur etic, A CE inhibit or, or long-acting dihy dropyridine \\ncalcium channel block er for almost all patients. Add second and thir d agents as \\nneeded t o achie ve eff ectiv e BP r eduction goals [IA]. \\n▪ Specific illnesses ma y guide the initial and subsequent choice of agents, \\ne.g.: \\n▪ ACE inhibit ors (ARB for those unable t o tolerate A CE inhibit ors) \\nfor patients with r enal disease, diabetes with either micr o- or \\nmacr oalbuminuria, or L V dysfunction \\n▪ Beta-block ers for those with CAD or CHF . \\n▪ Over 70% of individuals r equir e two or mor e drugs t o achie ve BP goals. A \\nfixed combination ther apy ma y be cost-eff ectiv e. Once a da y medications \\nincrease compliance and ar e preferred. \\nClinical Back ground \\nClinical Pr oblem  and Management Issues * Str ength of r ecommendation: \\nI= gener ally should be per formed; II = ma y be r easonable t o per form; III = gener ally should not be \\nperformed. \\nLevels of e vidence for the most significant r ecommendations \\nA = r andomiz ed contr olled trials; B=contr olled trials, no r andomization; C=obser vational trials; D=opinion \\nof exper t panel \\nIncidence \\nForty-thr ee million United States adults ha ve hyper tension, r epresenting 24% of the U.S. adult population; \\n20 million ha ve no medication pr escribed, and 12 million ar e on medication but not contr olled. Thus, \\nabout one out of four hyper tensiv e patients ar e adequately contr olled. Uncontr olled hyper tension r esults \\nin end stage or gan damage, which leads t o significant mor tality and morbidity . \\nTable 1. Selection of Initial and Subsequent A ntihyper tensiv e Drug(s) Based on Concurr ent Disease \\nStates \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 2 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 1}),\n",
       " Document(page_content='COPYCoexisting \\nCondition Disease Specific Agent* Relativ ely \\nContr a-\\nindicated \\nAgents** Comments \\nCardiovascular \\nAngina β block er; A CEI if L V dysfunction  Shor t-acting DHP CCBs ar e \\nrelativ ely contr aindicated for all \\ncoronar y artery disease. \\nMI Hist ory β block er, ACEI   \\nCHF – Syst olic ACEI, β block er; ARB if A CEI not \\ntolerated, \\naldoster one inhibit or Non-DHP \\nCCB, alpha \\nblock er HYD and nitr ate if A CEI and ARB \\nnot t olerated \\nβ block ers should be used in v ery \\nlow dosages and slowly titr ated. \\nCardiomy opathy \\n(Hyper trophic) β block er, non-DHP CCB diuretic, \\nACEI & ARB, \\nα1 block er, \\nDHP CCB Effects ma y be less with \\ncardioselectiv e β block ers \\nTachy cardia \\n(Supr a-\\nventricular) β block er, non-DHP CCB   \\nBradycardia/\\nhear t block  β block er, \\nNon-DHP \\nCCB, α2 \\nagonist  \\nAortic/Mitr al \\nRegur gitation ACEI, DHP CCB, ARB if A CEI not \\ntolerated   \\nMetabolic    \\nDiabetes ACEI, ARB  Concerns that thiazide diur etics \\nand β block ers ma y worsen \\nglucose contr ol and β block ers \\nmay mask hypogly cemia ha ve \\nlargely been r efuted as clinically \\ninsignificant \\nGout losar tan is uricosuric  Diuretic-induced hyperuricemia \\ndoes not r equir e treatment in \\nabsence of gout or kidne y stones. \\nEven with these, diur etics ma y be \\nrestar ted if uric acid is contr olled \\nto <6 mg/dl with allopurinol. \\nRenal Disease    \\nChronic Renal ACEI, ARB if A CEI not t olerated DHP CCB \\n(alone) Avoid potassium-sparing agents \\ndue t o incr eased risk of \\nhyperkalemia. Loop diur etics \\npreferred if cr eatinine is ≥ 2.5 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 3 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 2}),\n",
       " Document(page_content='COPY(GFR < 30 ml/min). \\nGU    \\nImpotence ACEI (ARB if A CEI not t olerated), \\nDHP CCB   \\nBilater al (or \\nequiv alent) \\nRenal Ar tery \\nStenosis β block er, DHP CCB ACEI and \\nARB  \\nPulmonar y    \\nReactiv e Air way \\nDiseases   β block ers should be star ted at \\nlow dose and slowly titr ated. \\nPsychiatric/\\nCNS    \\nHeadaches \\n(Vascular) β block er, non-DHP CCB  Verapamil (not diltiaz em) useful \\nfor cluster headaches and, t o \\nlesser extent, migr aines. \\nPregnancy    \\n methyldopa, β block er (ex cept \\natenolol and pr opranolol), \\ncalcium channel block er, \\nlabetalol, hy dralazine atenolol, \\npropranolol \\nACEI, ARB ACEI and ARB ar e absolutely \\ncontr aindicated. \\nDrug \\nInter actions    \\nCyclosporine \\nHTN β block er, DHP CCB   \\nLithium Usage β block er, DHP \\nCCB, Non-DHP CB Diuretics, \\nACEI and \\nARB Thiazides ma y incr ease le vel by \\n25-40%. P otassium sparing \\ndiuretics ha ve minor eff ects. \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 4 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 3}),\n",
       " Document(page_content='COPY* \\nAntihyper tensiv e \\nDrug Classes Abbr eviations Antihyper tensiv e Drug \\nClasses (cont.) Abbr eviations **Ma y still be used \\nunder cer tain \\ncircumstances \\nAlpha 1 block er α1 block er Direct v asodilat or NA \\nAngiotensin \\nconv erting \\nenzyme inhibit or ACEI Diuretic NA \\nAngiotensin II \\nrecept or \\nantagonist ARB Hydralazine HYD \\nBeta block er β block er Isosorbide Dinitr ate ISDN \\nCentr ally acting \\nalpha-2 agonist NA Non-dihy dropyridine calcium \\nchannel block er (e.g.-\\ndiltiaz em, v erapamil). Non-DHP \\nCCB \\nDihy dropyridine \\ncalcium channel \\nblock er \\n(e.g.-amlodipine, \\nfelodipine) DHP CCB   \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 5 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 4}),\n",
       " Document(page_content='COPYTable 2. A ntihyper tensiv e Medications: Common \\nDoses and Costs \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 6 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 5}),\n",
       " Document(page_content='COPYDrug Class \\n(generic name) Brand \\nName Usual Dosage Regimens 30 Da y Cost* \\nGeneric Brand \\nThiazide Diur etics \\nhydrochlor othiazide generic  12.5mg.daily 25mg \\ndaily 50 mg \\ndaily $4 n/a \\nchlor thalidone generic    25 mg \\ndaily $21 n/a \\nPotassium Sparing/Thiazide Combination Diur etics \\namiloride /HC TZ** generic   5 mg/50 mg daily $12 n/a \\ntriamter ene/HC TZ generic   37.5 mg/25 mg \\ndaily $11 n/a \\nspironolact one/\\nHCTZ generic   25 mg/25 mg daily $28 $43 \\nACE Inhibit ors \\ncapt opril Capoten  12.5 mg BID 25 mg \\nBID 50 mg TID $23-40 n/a \\nbenaz epril Lotensin 5 mg \\ndaily 10 mg daily 20 mg \\ndaily 40 mg \\ndaily $5 all $62 all \\nquinapril Accupril  10 mg daily 20 mg \\ndaily 40 mg \\ndaily $9 all $75 all \\nlisinopril Prinivil/\\nZestril 5 mg \\ndaily 10 mg daily 20 mg \\ndaily 40 mg \\ndaily $4-5 $42-67 \\nenalapril Vasotec 2.5 mg \\ndaily 5 mg daily 10 mg \\ndaily 10 mg BID $7-11 $107-272 \\nfosinopril Monopril  10 mg daily 20 mg \\ndaily 40 mg \\ndaily $8 all n/a \\ntrandolapril Mavik  1 mg daily 2 mg \\ndaily 4 mg daily $16 all $52 all \\nmoexipril Univ asc   7.5 mg \\ndaily 15 mg \\ndaily $18-30 $84-88 \\nramipril Altace  2.5 mg daily 5 mg \\ndaily 10 mg \\ndaily $6-7 $92-113 \\nperindopril Aceon   4 mg \\ndaily 8 mg daily 20-22 $79-96 \\nACE Inhibit or / Diur etic Combinations \\nbenaz epril/HC TZ Lotensin \\nHCT 5 mg/\\n6.25 mg \\ndaily 10 mg/12.5 mg daily 20 mg/\\n12.5mg \\ndaily $15 $56 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 7 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 6}),\n",
       " Document(page_content='COPYlisinopril/HC TZ Prinzide/\\nZestoretic 10 mg/\\n12.5 mg \\ndaily 20 mg/12.5 mg daily 20 mg/25 \\nmg daily $4-5 $45 all \\nfosinopril/HC TZ Monopril \\nHCT  10 mg/12.5 mg daily 20 mg/\\n12.5 mg \\ndaily $38 all $42 \\nquinapril/HC TZ Accur etic 10 mg/\\n12.5 mg \\ndaily 20 mg/12.5 mg daily 20 mg/25 \\nmg daily $23 all $79-96 \\nAngiotensin Recept or Block ers \\ntelmisar tan Micar dis  40 mg daily 80 mg \\ndaily $116 all $145 all \\nolmesar tan Benicar  20 mg daily 40 mg \\ndaily n/a $115-160 \\nvalsar tan Diovan 80 mg \\ndaily 160 mg daily 320 mg \\ndaily n/a $127-136 \\nirbesar tan Avapro  150 mg daily 300 mg \\ndaily $12-15 $92-111 \\ncandesar tan Atacand 8 mg \\ndaily 16 mg daily 32 mg \\ndaily $86-107 $95-128 \\neprosar tan Teveten 50 mg \\ndaily 400 mg daily 600 mg \\ndaily $98 $125 \\nlosar tan Cozaar  100 mg daily 50 mg BID $6-12 $113-156 \\nazilsar tan Edarbi  40 mg daily 80 mg \\ndaily n/a $132 \\nAngiotensin Recept or Block er / Diur etic Combinations \\nvalsar tan/HC TZ Diovan \\nHCT 40 mg/\\n12.5 mg \\ndaily 80 mg/12.5 mg daily 160 mg/\\n12.5 mg \\ndaily $16 all $120-142 \\ntelmisar tan/HC TZ Micar dis \\nHCC  80 mg/12.5 mg daily 80 mg/25 \\nmg daily n/a $145 all \\ncandesar tan/HC TZ Atacand \\nHCT  16 mg/12.5 mg daily 32 mg/\\n12.5 mg \\ndaily $60-63 $125 all \\nlosar tan/HC TZ Hyzaar  50 mg/12.5 mg daily 100 mg/\\n25 mg \\ndaily $6-8 $92-118 \\nolmesar tan/HC TZ Benicar \\nHCT 20 mg/\\n12.5 mg \\ndaily 40 mg/12.5 mg daily 40 mg/25 \\nmg daily n/a $160 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 8 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 7}),\n",
       " Document(page_content='COPYeprosar tan/HC TZ Teveten \\nHCT  600 mg/12.5 mg \\ndaily 600 mg/\\n25 mg \\ndaily n/a $132 \\nazilsar tan/C TD Edarb yclor  40 mg/ 12.5mg daily 40 mg/25 \\nmg daily n/a $120 \\nCalcium Channel Block ers \\nNon-DHP \\nverapamil SR Calan SR       \\ndiltiaz em Cardizem 30 mg \\nQID 60 mg TID  60 mg \\nQID 90 mg TID $6 $104 \\ndiltiaz em CD Cardizem \\nCD \\nDilacor 120 mg \\ndaily 180 mg daily 240 mg \\ndaily 300 mg \\ndaily $20-32 $328-554 \\nDHP  (dihy dropyridines) \\namlodipine Norvasc   5 mg \\ndaily 10 mg \\ndaily $2-4 $96-131 \\nfelodipine Plendil   5 mg \\ndaily 10 mg \\ndaily $19-29 $41-73 \\nnifedipine CC Adalat CC \\nProcar dia \\nXL  30 mg daily 60 mg \\ndaily 90 mg \\ndaily $15-28 $106-203 \\nnisoldipine Sular  20 mg daily 30 mg \\ndaily 40 mg \\ndaily $239-260 $429 \\nisradipine CR Dynacir c \\nCR   5 mg \\ndaily 10 mg \\ndaily $64-85 n/a \\nCalcium Channel Block er / A CE Inhibit or Combinations \\namlodipine/\\nbenaz epril Lotrel 2.5mg/10mg daily 5mg/\\n10mg \\ndaily 5mg/\\n20mg \\ndaily $10-21 $155-158 \\ntrandolapril/\\nverapamil Tarka 1mg/\\n240mg 2mg/180mg 2mg/\\n240mg 4mg/\\n240m all \\ndaily n/a $125 all \\nAldoster one A ntagonists \\nspironolact one Aldact one   25 mg \\ndaily 50 mg \\ndaily $12-18 $69-116 \\nepler enone Inspr a   50 mg \\ndaily 50 mg BID $54-128 $176-352 \\nBeta Block ers \\natenolol Tenormin  25 mg daily 50 mg \\ndaily 100 mg \\ndaily $4-5 $50-77 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 9 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 8}),\n",
       " Document(page_content='COPYpropranolol Inder al LA   40 mg \\nBID 80 mg BID $4-5 $150-300 \\nInder al XL  60 mg daily 80 mg \\ndaily 120 mg \\ndaily $27-54 $178-356 \\nlabetalol Trandate/\\nNormodyne  100 mg BID 200 mg \\nBID 300 mg \\nBID $24-41 $40-69 \\nnadolol Corgard  40 mg daily 80 mg \\ndaily 160 mg \\ndaily $96-153 $127-350 \\nmetoprolol tar trate Lopr essor   50 mg \\nBID 100 mg \\nBID $11-15 $134-268 \\nmetoprolol \\nsuccinate Toprol XL   100 mg \\ndaily 200 mg \\ndaily $27-45 $58-93 \\nByst olic  2.5 mg daily 10-20 \\nmg \\ndaily 40 mg \\ndaily  $78-159 \\nnebiv olol Coreg  3.125 BID 12.5-25 \\nmg BID 25 BID $6-7 $90-160 \\ncarvedilol Coreg CR 10mg \\ndaily 20 mg daily 40 mg \\ndaily 80 mg \\ndaily n/a $158 all \\nDirect V asodilat ors \\nHydralazine generic  25 mg TID 50 mg \\nTID 100 mg \\nTID $10-25 n/a \\nmino xidil generic   5mg \\nBID 20mg BID $11-28 n/a \\nCentr ally-acting alpha-2 agonists \\nclonidine Catapr es   0.1 TID 0.3 TID $8 all $180-275 \\nMethyldopa generic  25 0mg TID 500 mg \\nTID 1000 mg \\nTID $20-42 n/a \\nAlpha Block ers \\nDoxazosin Cardura  1mg daily 2mg \\ndaily 4mg daily $17-24 $66-70 \\nterazosin Hytrin  1mg daily 2mg \\ndaily 5mg daily $4-5 $42-43 \\nPrazosin Minipr ess  1mg BID 2mg \\nBID 5mg BID $17-33 $68-160 \\nRenin Inhibit ors \\naliskir en Tekturna   150 mg \\ndaily 300mg \\ndaily n/a $112-142 \\nOther Diur etics \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 10 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 9}),\n",
       " Document(page_content='COPYTorsemide Demadex   5 mg \\ndaily 10 mg \\ndaily $11-13 $54-60 \\n(Furosemide –generic or Lasix – has no blood pr essur e indication, only v olume contr ol.) \\nTable 3. Err ors in Measur ement of Blood \\nPressur e \\n• Back not \\nsuppor ted \\n• Arm not \\nsuppor ted \\n• Elbow t oo \\nhigh \\n• Elbow t oo \\nlow \\n• Missed \\nauscultat ory \\n• Feet not on \\nground • Pseudo-\\nhyper tension \\n• Atrial \\nfibrillation \\n• Pain or \\nanxiety \\n• Acute \\nsmoking \\n• Acute \\ncaffeine \\n(<30 min.) \\n• Acute \\nethanol (<2 \\nhours) \\n• Talking \\nduring BP \\nreading • Menstrual phase \\n• Chronic caff eine ingestion \\n• Phenylephrine nasal spr ay \\n• Cuff self-inflation \\n• Examinee and examiner discor dance in \\nsex or r ace \\n• Bell vs diaphr agm of stethoscope \\n• Room temper ature \\n• Thin shir tslee ve under cuff (gr owing \\nevidence, not univ ersally endorsed) \\n• Gauge \\ninaccur ate \\n• Cuff not \\ncorrect siz e \\nTable 4. Classification of Office BP Readings \\nCategor y Syst olic Diast olic \\nNormal <120 and <80 \\nPrehyper tension 120-139 or 80-89 \\n• Stage 1 140-159 or 90-99 \\n• Stage 2 ≥160 or ≥100 * Pricing information for br and drugs, A verage Wholesale Price minus 10% fr om Red Book Online 11/1/13. \\nFor generic drugs, Maximum Allowable Cost plus $3 fr om BCBS of Michigan M AC List, 11/1/13. ** HC TZ \\n= hydrochlor othiazide, C TD = chlothalidone \\nFaulty T echnique Patient Related No eff ect on BP r eadings \\nFaulty BP E quipment \\nHyper tension \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 11 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 10}),\n",
       " Document(page_content='COPYTable 5. Re versible Causes of Sustained \\nElevated Blood Pr essur e Readings \\n• NSAIDs * \\n• oral \\ncontr aceptiv e \\nagents \\n• glucocor ticoid or \\nminer alocor ticoid \\nsteroids • appetite \\nsuppr essants \\n• anti-\\ndepr essants \\n• MAO \\ninhibit ors \\n• cyclosporine \\n• erythropoietin • alcohol > 2 \\ndrinks/da y \\n• sedentar y \\nlifestyle • High \\nsodium \\n(esp. \\nelderly or \\nAfrican-\\nAmerican) \\n* inter feres with \\nantihyper tensiv e \\nmedications  \\n• cocaine \\n• amphetamines \\n• anabolic \\nsteroids • Sleep \\napnea \\nRationale for Recommendations \\n• Diagnosis of hyper tension \\n• Initial e valuation of newly diagnosed patient \\n• Treatment of hyper tension \\n• Monit oring blood pr essur e contr ol \\nDiagnosis of Hyper tension Medications: Medications \\n(continued): Lifestyle fact ors Diet \\nIllicit drugs Associated \\nConditions \\nRecommendations ar e organiz ed under headings for: \\nPerforming BP measur ement.  BP readings need t o be per formed accur ately t o provide useful \\ninformation. BP in the office should be check ed after 5 minutes of sitting quietly in a chair , with f eet on the \\nfloor , and arm suppor ted at the hear t level, and the r esults r ecor ded on the medical r ecor d. Standar dizing \\nthe use of the same arm b y all staff can facilitate comparisons for sequential measur ement. The choice \\nof which arm does not matter if at the initial measur ement ther e are no diff erences between blood \\npressur es tak en on both sides. Caff eine, ex ercise, and smoking should be a voided for at least 30 minutes \\nprior t o measur ement. (See Appendix for detail about de vices and pr oper technique.) P atients should be \\ninformed of the readings, interpr etation and necessar y follow-up if indicated. \\nFrequency of BP scr eening.  Frequency depends on patient risk status r egar ding hyper tension. \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 12 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 11}),\n",
       " Document(page_content='COPY• If normotensiv e (&lt;120/80) , at least e very 2 y ears (curr ent exper t opinion). Howe ver one \\nshould consider BP measur ement for e very adult visit. \\n• If risk fact ors, at least annually . \\n• Home blood pr essur e monit oring (HBPM) – P atient or car egiver recor ds blood pr essur es at \\nhome with a blood pr essur e cuff. This r equir es knowledge and tr aining in pr oper technique. \\nUpper arm BP cuffs ar e preferred, since wrist and finger monit ors ar e not r eliable. Pr oper \\ntechnique and calibr ation of home BP cuffs should be v erified in a clinic setting if HBPM is t o be \\nutiliz ed for clinical decision making. \\n• Ambulat ory blood pr essur e monit oring (ABPM) – A utomated cuff sent home fr om the clinic, \\nworn for a pr e-specified period of time (usually 24 hours). It is expensiv e, but is r eliable and has \\nbeen shown t o be an independent pr edict or of car diovascular morbidity and mor tality when \\nadded t o office based BP measur es. \\n• White coat hyper tension ( WCH)  refers t o patients with ele vated BP at office visits, but normal \\nBP outside the office. This condition is common (&gt;20% of patients with ele vated BP) and ma y \\nresult in o vertreatment if unr ecogniz ed. Both HBPM and ABPM can help identify WCH. \\nDocumentation of WCH r esults in decr eased drug cost, with no change in L V mass, \\ncardiovascular outcomes, or well being. WCH ma y carr y a higher long term risk of hyper tension, \\nbut at least one study has not shown an incr ease in risk. \\n• Mask ed hyper tension refers t o patients with tar get BP at clinic, but ele vated home BP . This \\ncondition ma y be nearly as common as WCH. These patients ma y have LVH or other tar get \\norgan damage despite normal office BP . Both HBPM and ABPM can help identify mask ed \\nhyper tension, r esulting in mor e aggr essiv e medication r egimens and impr oved car diovascular \\noutcomes. \\nInitial E valuation of Newly Diagnosed P atients Although a single, car efully tak en BP r eading ma y predict futur e car diovascular risk, risk is better identified \\nby taking the mean BP le vel from r ecor dings o ver se veral visits. \\nHTN classification and follow-up assessment.  The a verage initial BP r eadings should be staged \\naccor ding t o JNC 7 exper t opinion guidelines (T able 4). \\nFor pr ehyper tension (120-139 / 80-89 mm Hg), measur e BP annually . \\nIf the BP a verage is ≥140/90, consider assessing for and corr ecting the r eversible causes of hyper tension \\n(Table 5). A ortic regur gitation ma y be a cause of isolated syst olic hyper tension. \\nBP monit oring . BP can be monit ored at home in two wa ys. \\nHBPM and ABPM identify patients whose BP at clinic visits diff ers fr om BP outside the office. The y ma y \\nalso be useful in r esistant hyper tension. \\nCurr ently , reimbursement for ABPM b y Medicar e is co vered only for suspected WHC, defined b y 3 or mor e \\noffice visit BPs >140/90 mm Hg, at least two documented BPs outside the office <140/90 mm Hg, and no \\nevidence of tar get or gan damage. \\nHistory. Once the diagnosis of hyper tension is made, the clinician should determine b y hist ory and \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 13 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 12}),\n",
       " Document(page_content='COPY• Cardiovascular r eview of systems, including known dur ation of hyper tension \\n• Sympt oms or pr evious personal/family hist ory that helps t o identify secondar y hyper tension \\n• Presence or absence of other car diovascular risk fact ors \\n• Psychosocial and envir onmental fact ors that ma y influence BP contr ol \\n• Medications being tak en \\n• Two or mor e BP measur ements separ ated b y 2 minutes with the patient either supine or seated \\n• Verification in the contr alater al arm \\n• Body mass index (BMI), calculated b y weight (k g)/ [height (m)]2 (possibly waist cir cumf erence) \\n• Funduscopic examination for ar teriolar narr owing, nicking, hemorrhages, exudates, etc. \\n• Neck examination for car otid bruits, distended v eins, or enlar ged thyr oid \\n• Hear t/lung examination \\n• Abdominal examination for enlar ged kidne ys, masses, distended bladder , renal bruits, aor tic \\naneur ysm \\n• Extremity examination for pedal pulses and edema \\n• Neur ological assessment, par ticularly for signs of cer ebrovascular disease \\n•  Potassium • Urinalysis \\n• Blood glucose • Lipid panel \\n• Creatinine • EKG \\n• Calcium • Hemat ocrit \\n• Chronic or acute kidne y disease physical examination whether the patient has e vidence suggesting secondar y hyper tension, as well as \\nother car diovascular risk fact ors. The hist ory should focus on the following: \\nPhysical examination.  Based on exper t opinion the JNC 7 r ecommendations for the physical examination \\nof hyper tensiv e patients ar e: \\nLabor atory tests and diagnostic pr ocedur es. \\nEssential hyper tension . Consider the following tests befor e ther apy is initiated. Scr eening for diabetes is \\nparticularly impor tant. \\nSecondar y and/or complicated hyper tension . Consider other testing and/or r eferral when secondar y \\nhyper tension or complicated hyper tension (does not r espond t o usual measur es, pr e-existing contr olled \\nhyper tension becomes uncontr olled, sudden onset of hyper tension, and/or malignant hyper tension) is \\nsuspected. Hist ory and the abo ve labor atory scr eening ma y be helpful in detection. \\nSecondar y hyper tension and complicated hyper tension etiologies include: \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 14 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 13}),\n",
       " Document(page_content=\"COPY• Reno vascular hyper tension \\n• Sleep apnea \\n• Medications or illicit drugs \\n• Chronic kidne y disease \\n• Reno vascular disease \\n• Primar y aldoster onism \\n• Coar ctation of the aor ta \\n• Chronic ster oid ther apy and Cushing' s syndr ome \\n• Pheochr omocyt oma \\n• Thyr oid or par athyr oid disease \\n• LVH \\n• CHF \\n• Angina \\n• Stroke or TI A \\n• Chronic kidne y disease (includes \\nmicr oalbuminu-ria and \\nproteinuria) \\n• Peripher al ar terial disease \\n• Retinopathy \\n• MI \\n• CABG \\n• CVA \\n• TIA • Smoking \\n• Obesity (BMI ≥30 k g/m2) \\n• Physical inactivity \\n• Dyslipidemia \\n• Diabetes \\n• Estimated GFR < 60 mL/min) \\n• Age (>55 for men, >65 for women) \\n• Family hist ory of pr ematur e car diovascular \\ndisease (men <55 or women <65) disease \\nTreatment of Hyper tension Medications and other r eversible causes ar e described fur ther in T able 5. \\nRisk Str atification. The risk of car diovascular disease in patients with hyper tension is determined not only \\nby the le vel of BP but also b y the pr esence or absence of tar get or gan damage: \\nCurr ent diagnoses: \\nHistory of: Other risk fact ors: \\nTreatment BP goal. The goal depends on the pr esence of other risk fact ors. \\nGoal if no risk fact ors. Clinical trial data r eviewed b y the Se venth Repor t of the Joint National Committee \\n(JNC 7) suppor t reducing SBP t o < 140 mmHg and DBP t o < 90 mmHg. This has been confirmed b y the \\npanel members of the Eighth Joint National Committee for those aged below 60 y ears. F or those aged 60 \\nyears and o ver, the latter r ecommends r educing SBP t o <150 mmHg and DBP t o <90 mmHg. A sustained \\ndecr ease in SBP of 10 mm Hg or DBP of 5-6 mm Hg for patients with hyper tension decr eases the risk of \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 15 of 30\", metadata={'source': './mm_htn_guidelines.pdf', 'page': 14}),\n",
       " Document(page_content='COPYstroke by 35-40% and decr eases the chance of cor onar y hear t disease b y 20-25%. \\nGoal if diabetes or end or gan damage . The goals for blood pr essur e treatment in diabetes ha ve been \\nevaluated in se veral randomiz ed trials. \\nFor diast olic blood pr essur e, a tar get of 90 and possibly 80 mmHg pr ovides mark ed benefits. Caution is \\nsuggested when diast olic BP falls below 70 mmHg. Mor tality incr eased when patients with diabetes had \\ndiast olic BP below 70. \\nSyst olic blood pr essur e has not been e valuated as rigor ously . For patients with ele vated blood pr essur e \\nand other end or gan damage (e.g. r etinopathy , CHF , CAD , PVOD, cerebrovascular disease), aggr essiv e \\ntreatment of H TN pr ovides significant impr ovements in clinical outcomes. F ew studies ha ve tar geted or \\nachie ved syst olic pr essur es below 140 mmHg. Howe ver, the a vailable data suggest that a syst olic tar get \\nof < 140 mmHg is r easonable. \\nTreatment selection.  While lif estyle modification is alwa ys recommended, the addition of medications \\ndepends on disease se verity and other risk fact ors. \\nPatients with pr ehyper tension but without risk fact ors or tar get or gan damage (T OD) should ha ve \\nlifestyle modification r ecommended. \\nPatients with Stage 1 hyper tension and no other risk fact ors can be r ecommended for a trial of lif estyle \\nmodification for up t o 12 months. With r ecent e vidence suggesting that early tr eatment t o goal blood \\npressur e levels ma y attenuate the expr ession of hyper tension and impr ove clinical outcomes, mor e \\nexper ts ar e recommending both medication and lif estyle modification initially , with plans t o reduce or \\neliminate drug ther apy as lif estyle goals ar e achie ved. \\nPatients with Stage 2 hyper tension or with either diabetes, or any T OD should ha ve drug ther apy in \\naddition t o lifestyle modification. Initial combination ther apy with a thiazide plus an additional agent is \\nuseful (or other combinations). Additionally , patients that ar e felt to ha ve resistance t o prior ther apy or \\npossibly less compliant ma y achie ve better contr ol with initial combination ther apy. \\nLifestyle modifications.  Clinical trials ha ve shown that lif estyle modifications can lower BP . Lifestyle \\nmodifications ar e best initiated and sustained thr ough an educational par tnership between the patient \\nand a multidisciplinar y health car e team. While team members ma y vary by clinical setting, beha vior-\\nchange str ategies should include nutrition, ex ercise, and smoking cessation ser vices. \\nWeight r eduction and maintenance.  Many individuals who ar e both o verweight and hyper tensiv e can \\nlower their BP with weight r eduction. The eff ect is usually e vident in the early stages of weight loss and \\nfrequently occurs with only a ten pound r eduction in weight. \\nModification of dietar y sodium . The curr ent r ecommendation is t o lower sodium intak e to less than 2.4 \\ngrams per da y. Encour age patients t o lower their sodium intak e by not adding salt t o their food or in \\ncooking; limiting pr ocessed, conv enience, or fast foods; and r eading food labels for sodium content. \\nWater softeners contribute sodium t o the water and ma y be significant. \\nModer ation of alcohol intak e. Patients should not ex ceed a daily alcohol intak e of 1 ounce of ethanol. \\nThis amount is contained in 2 ounces of 100 pr oof whisk ey, 8 ounces of wine, or 24 ounces of beer . \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 16 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 15}),\n",
       " Document(page_content='COPY\\n• Once daily administr ation \\n• Reduction in CV complications demonstr ated in clinical trials \\n• Choice of agent(s) that also tr eat concurr ent conditions \\n• Least potential disruptiv e side-eff ects based on concurr ent conditions or lif estyles \\n• Least expensiv e (both in pharmaceutical and labor atory monit oring costs) \\n• Fixed combination ther apy can be mor e cost-eff ectiv e and ma y impr ove compliance. Some \\npatients ma y benefit fr om beginning with fix ed combination ther apy (e.g., Stage 2 hyper tension \\nor patients r esistant t o monother apy in the past). Adequate physical activity . Regular aer obic physical activity ma y be beneficial for both pr evention and \\ntreatment of hyper tension. It ma y enable weight loss, impr ove functional health status, and diminish \\nmortality and risk for car diovascular disease. Thir ty to for ty-fiv e minutes of brisk walking thr ee or four \\ntimes weekly is adequate and eff ectiv e. Resistiv e isot onic activities as sole ex ercise ar e not \\nrecommended t o lower BP in hyper tensiv e patients. \\nTobacco a voidance . All smok ers should be off ered assistance in smoking cessation and str ongly advised \\nto quit. \\nPotassium . High dietar y potassium ma y protect against hyper tension de velopment. Hypokalemia ma y \\nexacerbate hyper tension and induce v entricular arrhythmia. P otassium sparing diur etics and A CE \\ninhibit ors r etain potassium and magnesium wher eas simple potassium chloride r eplacement does not \\nreplace magnesium. \\nOther dietar y fact ors. Calcium supplementation ma y result in a v ery small r eduction in BP (syst olic -1.27 \\nmm Hg; diast olic -0.24 mm Hg). No definitiv e data suggest magnesium supplementation lowers blood \\npressur e. Dietar y fats ha ve no eff ect on blood pr essur e. Acute caff eine ingestion ma y ele vate BP; \\nhowe ver, tachyphylaxis t o chr onic ingestion attenuates this eff ect. A diet low in sodium and satur ated \\nfats, and high in v egetables, fruits, and low fat dair y products has been shown t o lower blood pr essur es \\n(the \"D ASH\" diet). \\nDrug ther apy. Hyper tension is a chr onic disease. Thus, the choice of which medication(s) t o prescribe has \\nlong term implications. \\nDrug selection.  Data fr om a v ery large multicenter RC T suppor ted b y smaller studies demonstr ate that \\nmoder ate-t o-high dose thiazide diur etics (chlor thalidone 25 mg/da y) ar e as good as any other class of \\nagents in r educing car diovascular adv erse outcomes, and superior in secondar y outcomes such as str oke \\nand CHF . Most patients will r equir e two or mor e drugs t o achie ve contr ol, and a f ew will not t olerate \\nthiazides. The choice of additional or alternativ e medication should be individualiz ed to achie ve the tar get \\nBP and the following goals: \\nAll agents within  a class ha ve similar physiological action, ex cept calcium channel block ers and beta \\nblock ers, which ha ve sub-classes with diff erent physiological eff ects.  If monother apy is not eff ectiv e in \\nreaching the BP goal, the addition or substitution of a diff erent class with diff erent physiological action is \\nindicated. Combining medications fr om the same class is not eff ectiv e. Table 2 shows costs of drug \\ntreatment for v arious antihyper tensiv e agents. \\nDiuretics, beta block ers, A CE inhibit ors, and long-acting dihy dropyridine CCBs ha ve been shown in \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 17 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 16}),\n",
       " Document(page_content=\"COPYrandomiz ed contr olled trials t o reduce car diovascular morbidity and mor tality . The ALLH AT study was a \\nlarge multicenter dir ect comparison RC T designed t o determine if the older or newer agents ar e mor e \\neffectiv e in pr evention of car diovascular morbidity and mor tality . It compar ed tr eatment star ting with a \\nthiazide diur etic, an A CE inhibit or, a long-acting dihy dropyridine CCB, and an alpha-block er. Beta block ers \\nand centr ally-acting agents wer e used as the second step drugs; almost thr ee-four ths of patients r equir ed \\ntwo or mor e drugs. Beta block ers wer e the most commonly used second agent. The alpha block er arm \\nwas discontinued early because of an ex cess of adverse outcomes. The other agents per formed equally \\nin primar y outcome (cor onar y endpoints), but the thiazide (chlor thalidone), in moder ate t o high doses, \\nwas superior in secondar y outcomes (str oke and CHF). This finding was consistent acr oss age and r ace, \\nand in all subgr oups including patients with diabetes, cor onar y disease, and hyperlipidemia. \\nExistence of other risk fact ors, co-morbidities, and concern for unt owar d drug eff ects ma y influence initial \\ndrug selection. A CE inhibit ors, ARB' s, and CCB' s ma y be initial options. Beta block ers ar e not pr eferred as \\ninitial ther apy in the elderly unless compelling other conditions exist, e.g., cor onar y artery disease (see \\nTable 1). Recent meta-analyses suggest that beta block ers ma y be less eff ectiv e in str oke reduction when \\ncompar ed to other classes of antihyper tensiv e ther apy. Beta block er usage for H TN ma y be def erred \\nunless CAD or CHF exists. \\nFor African Americans without DM or CKD , a thiazide diur etic and/or CCB ma y be consider ed as first and \\nsecond line antihyper tensiv e medications. Howe ver, an A CEI or ARB ma y be mor e appr opriate for African \\nAmericans with DM and/or CKD with estimated GFR of <60 ml/min and also for those wher e a clinical \\nsuspicion of milder CKD exists, e.g., positiv e for micr oalbuminuria. This r ecommendation diff ers fr om \\nJNC 8, which r ecommends a thiazide diur etic or CCB as initial antihyper tensiv e ther apy for African \\nAmericans, including for those with diabetes. \\nNo clear guidelines exist r egar ding whether specific drug combinations impar t superior clinical outcomes \\n(e.g., A CEI/CCB vs. A CEI/diur etic. Lar ge, well-designed trials (A CCOMPLISH with benaz epril/amlodipine \\nvs. benaz epril/HC TZ, A CCELERA TE with aliskir en and amlodipine vs. either alone) r aise the possibility that \\na combination of a block er of the r enin-angiotensin system and calcium channel block er ma y be superior \\nto other combinations and single agents. Curr ently , the combinations of A CEI/ARB, A CEI/dir ect r enin \\ninhibit or (DRI), or ARB/DRI ar e not r ecommended in H TN management. \\nDiuretics . Thiazide diur etics ha ve traditionally been the initial tr eatment for most patients with \\nhyper tension. Although the trials that showed a decr ease in car diovascular morbidity and mor tality used \\nmoder ate t o high dose diur etics, higher dosages of thiazide diur etics ha ve shown only minimal \\nimpr ovement in BP contr ol. Consequently , the maximum suggested dosage of thiazide diur etics has been \\nlower ed in or der t o avoid metabolic side-eff ects. The r ange of hy drochlor thiazide is 12.5mg t o 50 mg each \\nmorning. In patients mor e vulner able t o side eff ects, such as the elderly , even this r ange should be\", metadata={'source': './mm_htn_guidelines.pdf', 'page': 17}),\n",
       " Document(page_content='inhibit or (DRI), or ARB/DRI ar e not r ecommended in H TN management. \\nDiuretics . Thiazide diur etics ha ve traditionally been the initial tr eatment for most patients with \\nhyper tension. Although the trials that showed a decr ease in car diovascular morbidity and mor tality used \\nmoder ate t o high dose diur etics, higher dosages of thiazide diur etics ha ve shown only minimal \\nimpr ovement in BP contr ol. Consequently , the maximum suggested dosage of thiazide diur etics has been \\nlower ed in or der t o avoid metabolic side-eff ects. The r ange of hy drochlor thiazide is 12.5mg t o 50 mg each \\nmorning. In patients mor e vulner able t o side eff ects, such as the elderly , even this r ange should be \\nappr oached with caution. The most studied thiazide is chlor thalidone, though hy drochlor othiazide is the \\npredominant pr escription thiazide in the USA. \\nSide eff ects.  Thiazide diur etics incr ease the fr equency of sexual dysfunction in men and women and \\ninitially ma y cause interruptions in daily r outine for micturition. Thiazides cause a shor t-term incr ease in \\nLDL cholester ol; howe ver, long-term trials ha ve shown minimal change and outcome studies show no \\nclinical impact. Thiazides slightly incr ease risk for diabetes (ALLH AT). While small changes in LDL and \\nglycemic contr ol ar e not contr aindications, the clinical impact of these metabolic aberr ations has y et to be \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 18 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 17}),\n",
       " Document(page_content='COPYelucidated. Thiazides can incr ease uric acid and pr ecipitate attacks of gout. Hypokalemia is uncommon at \\nusual (12.5-25 mg) doses but occurs r elativ ely often at doses of 50 mg or mor e. \\nLoop diur etics.  These diur etics ar e preferred for individuals with r enal impairment (serum cr eatinine ≥ 2.5 \\nmg/dl) and individuals aller gic t o thiazide diur etics. Loop diur etics ar e useful for r educing pr eload, which \\ncontributes t o hyper tension in r enal-impair ed individuals. Hypokalemia is less common due t o the r enal \\nimpairment, but should still be monit ored. Loop diur etics ar e not as lik ely as thiazide diur etics t o cause \\ngout. \\nAngiotensin conv erting enzyme (A CE) inhibit ors. As a class, A CE-inhibit ors ha ve similar actions and side \\neffects, with the only major diff erence being dur ation of action. A CE inhibit ors r educe BP with gener ally \\nfew side eff ects and slow the decline of r enal function in most diseases. The r enopr otectiv e eff ect ma y be \\naugmented when combined with angiotensin r ecept or block er. Ramipril was shown in a r andomiz ed \\ncontr olled trial t o decr ease car diovascular e vents in hyper tensiv e and normotensiv e individuals with \\nsystolic hear t failur e over placebo. Howe ver, newer trials ha ve not shown r enin-angiotensin blockade t o be \\nsuperior t o other medications in decr easing morbidity and mor tality . Onset of diabetes was not pr evented \\nby ramipril in a study dir ectly addr essing this issue. \\nSide eff ects . Angioedema is a r are side eff ect (0.1-0.7%), which ma y be lif e-thr eatening and ma y occur at \\nany point in the tr eatment. The incidence ma y be higher in African Americans. Although r enal ar tery \\nstenosis per se is not a contr aindication for A CE ther apy, renal impairment ma y occur in patients with \\nbilater al renal ar tery stenosis or unilater al renal ar tery stenosis with a single kidne y. All in this class induce \\ncough equally , which ma y be disabling enough with some patients t o result in the need t o discontinue the \\ndrug; cough occurs mor e often in women. This class is contr aindicated in pr egnancy . \\nAngiotensin II r ecept or antagonists (ARB)  displace angiotensin II (AII) fr om its type 1 r ecept ors. Losar tan \\nand irbesar tan ha ve been shown in r andomiz ed, double-blind trials in diabetics with micr oalbuminuria or \\nazotemia t o decr ease the de velopment of fr ank pr oteinuria or pr ogression t o renal failur e requiring \\ndialysis or tr ansplantation. In patients who ha ve syst olic hear t failur e and ar e int olerant t o an A CEI \\nbecause of cough, ARBs ar e recommended. \\nSide eff ects . Angioedema has been r arely repor ted with Losar tan, but has occurr ed in patients with prior \\nangioedema on A CE inhibit ors. Losar tan has a uricosuric eff ect (i.e. incr eases ex cretion of uric acid, \\nlowering concentr ation in blood) that is unique compar ed to others in this class. Losar tan ma y be less \\nefficacious compar ed to others in this gr oup at lowering BP and should be used twice a da y. This class is \\ncontr aindicated in pr egnancy . \\nCalcium channel blocking (CCB) agents . Ther e are thr ee classes of calcium channel blocking agents \\nbased on diff erent calcium channel r ecept ors, all with diff erent physiological eff ects and side eff ects:', metadata={'source': './mm_htn_guidelines.pdf', 'page': 18}),\n",
       " Document(page_content=\"Side eff ects . Angioedema has been r arely repor ted with Losar tan, but has occurr ed in patients with prior \\nangioedema on A CE inhibit ors. Losar tan has a uricosuric eff ect (i.e. incr eases ex cretion of uric acid, \\nlowering concentr ation in blood) that is unique compar ed to others in this class. Losar tan ma y be less \\nefficacious compar ed to others in this gr oup at lowering BP and should be used twice a da y. This class is \\ncontr aindicated in pr egnancy . \\nCalcium channel blocking (CCB) agents . Ther e are thr ee classes of calcium channel blocking agents \\nbased on diff erent calcium channel r ecept ors, all with diff erent physiological eff ects and side eff ects: \\nverapamil, diltiaz em, and dihy dropyridines. All long acting DHP CCB' s have been shown t o reduce blood \\npressur e and car diovascular e vents. \\nOf the dihy dropyridine CCB' s, the longer-acting agents (e.g. amlodipine, f elodipine, nislodipine) mak e \\nsingle daily dosing possible. These drugs pr ovide the most r eliable and significant blood pr essur e \\nreduction in most patient subtypes. The y are par ticularly eff ectiv e in str oke reduction and ha ve been \\nshown t o reduce o verall CVD risk. The shor t-acting agents ar e not indicated for hyper tension. \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 19 of 30\", metadata={'source': './mm_htn_guidelines.pdf', 'page': 18}),\n",
       " Document(page_content=\"COPY• Acute cor onar y syndr ome.  Shor t-acting dihy dropyridines should be a voided in the first 24-48 \\nhours of an acute cor onar y syndr ome. \\n• Chronic kidne y disease.  Dihy dropyridines should be a voided as a single agent for patients with \\nmicr oalbuminuria, as the y will worsen pr otein loss and r enal function, but ma y be used in \\ncombination with ARB or A CE inhibit ors. \\n• Chronic CAD . Verapamil has shown t o be as eff ectiv e as a beta-block er in patients with CAD or \\nremote hist ory of MI. The long-acting dihy dropyridine agents ma y be used in patients with \\nangina; howe ver, some f eel that the y only should be used when combined with a beta block er. \\nAll CCB' s can be used in hyper tensiv e patients with chr onic CAD t o reduce anginal episodes  \\n• Aortic regur gitation. Nif edipine ma y be useful in hyper tensiv e patients with aor tic regur gitation. \\nSide eff ects . Edema ma y occur and is mor e pronounced with the dihy dropyridine agents. Some eff ects with specific diseases include: \\nBradycardia is a side eff ect of v erapamil and diltiez em, but r enders them useful agents in the tr eatment of \\natrial fibrillation/SVT). V erapamil has mor e pronounced br adycardia eff ects and often r esults in \\nconstipation. V erapamil and diltiaz em ma y incr ease risk for statin my opathy (cyt ochr ome 3A4 inhibition). \\nAldoster one inhibit ors. Spironolact one and epler enone ar e used in cer tain conditions associated with \\nhyper tension, such as r esistant hyper tension, hyper aldoster onism, and potassium wasting. Howe ver, \\nwhen used in patients with chr onic kidne y disease, or concurr ently with potassium sparing agents (A CEI, \\nARB, triamter ene), the y carr y significant risk for life-thr eatening hyperkalemia. Combination ther apy is \\ngener ally r estricted t o patients with syst olic hear t failur e, and r equir es close follow-up. Gynecomastia and \\nbreast pain ar e common side eff ects with spir onolact one, causing discontinuation in about 10%. \\nBeta block ers have been shown t o reduce car diovascular morbidity and mor tality in contr olled clinical \\ntrials for both diast olic and isolated syst olic hyper tension. Howe ver, one study showed that diur etics ar e \\nsuperior t o beta-block ers for str oke reduction, and another showed that losar tan is superior t o beta \\nblock er for CVD r eduction. The r esults of thr ee meta analyses suggest that other anti-hyper tensiv e agents \\nare superior t o most beta-block ers for initial ther apy. In addition, atenolol has poor er outcomes when \\ncompar ed to other beta-block ers (an ex cess str oke risk of 17%). \\nBeta block ers ar e indicated for patients with cor onar y disease or CHF unless specific contr aindications or \\ndocumented int olerance exists. Cer tain beta block ers (e.g., car vedilol) also ha ve alpha blocking pr oper ties \\nand ar e useful for maintenance ther apy of hear t failur e. Discussion r egar ding other pr oper ties of beta \\nblock ers, such as B1 selectivity and lipid solubility , are be yond the scope of this guideline. \\nWhile a tar get hear t rate of <60/minute has been suggested in using beta block ers for patients with \\nsystolic hear t failur e, no tar get has been established for patients with uncomplicated hyper tension. \\nSide eff ects . Occasionally fatigue and uncommonly impotence ar e side eff ects at the r ecommended low \\ndoses. Beta-1 block ers pr oduce the same dr amatic r eduction in angiotensin II le vels as A CE inhibit ors,\", metadata={'source': './mm_htn_guidelines.pdf', 'page': 19}),\n",
       " Document(page_content='and ar e useful for maintenance ther apy of hear t failur e. Discussion r egar ding other pr oper ties of beta \\nblock ers, such as B1 selectivity and lipid solubility , are be yond the scope of this guideline. \\nWhile a tar get hear t rate of <60/minute has been suggested in using beta block ers for patients with \\nsystolic hear t failur e, no tar get has been established for patients with uncomplicated hyper tension. \\nSide eff ects . Occasionally fatigue and uncommonly impotence ar e side eff ects at the r ecommended low \\ndoses. Beta-1 block ers pr oduce the same dr amatic r eduction in angiotensin II le vels as A CE inhibit ors, \\nand the two agents t ogether ha ve an additiv e eff ect. Though beta block ers ma y raise trigly cerides and \\nlower HDL cholester ol, these eff ects ha ve not been found t o be clinically significant in outcome studies. \\nRenin inhibit ors are a no vel wa y of blocking the r enin-angiotensin-aldoster one system (RAAS). The first \\ndrug in this class is aliskir en. The drug has been shown t o lower blood pr essur e alone or in combination \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 20 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 19}),\n",
       " Document(page_content='COPY\\nMonit oring Blood Pr essur e Contr ol with other antihyper tensiv es, but its eff ects on clinical outcomes is unknown. Aliskir en should be used as \\na four th line agent in patients who ha ve failed standar d ther apy. \\nSide E ffects.  As with other RAAS agents, aliskir en can cause an incr ease in serum cr eatinine and \\npotassium especially is used in combination with an A CE inhibit or or ARB. This class is contr aindicated in \\npregnancy . \\nPeripher al alpha block ers. Alpha block ers should not be used as initial ther apy but ma y be added t o a \\nthiazide or other outcome-impr oving agent for additional BP contr ol or when pr ostatism tr eatment is \\ndesir ed. \\nSide eff ects:  Alpha block ers ma y cause first dose syncope, so ar e gener ally star ted at bedtime and slowly \\ntitrated up in dose. The y ma y cause fluid r etention and edema. The ALLH AT study showed a 25% incr ease \\nin car diac e vents in the do xazosin vs. chlor thalidone gr oup. \\nCentr ally-acting alpha-2 agonists  are less often used due t o their side-eff ects. The y have no e vidence of \\noutcome benefit. Methyldopa r emains a first line agent in pr egnancy . \\nSide eff ects.  May induce br adycardia; dr y mouth and sedation ar e common. Rebound hyper tension ma y \\noccur with sudden discontinuation of clonidine. \\nDirect v asodilat ors. These drugs ar e four th line agents for essential hyper tension and should be used in \\npatients who ha ve failed standar d ther apy. Direct v asodilat ors induce r eflex tachy cardia and thus should \\nbe combined with a beta block er or non-dihy dropyridine calcium channel block er. Due t o incr eased fluid \\nretention, the y should also be combined with a diur etic. These agents ha ve not been shown t o reduce left \\nventricular hyper trophy . The y are thir d or for th line agents, sometimes useful in r efractory hyper tension. \\nHydralazine ma y produce a lupus er ythemat osus-lik e syndr ome; the syndr ome is extr emely r are when the \\ndaily dose is less than 200 mg. Side eff ects include headache, palpitations, anor exia, and nausea. A t least \\ntwice daily dosing r equir ements limit the usefulness of this drug. Hy dralazine has shown benefit in CHF \\nwhen combined with a nitr ate. \\nMino xidil is eff ectiv e in tr eating the se verest forms of hyper tension, although it is used less fr equently \\ntoday because A CE inhibit ors and calcium channel block ers ma y be as eff ectiv e. Side eff ects include \\nhyper trichosis and fluid accumulation in ser ous ca vities, including the pericar dium. \\nNo studies demonstr ate the most appr opriate monit oring of BP and follow-up. The following is a \\nconsensus opinion of the guideline team. \\nBlood pr essur e measur ement. All patients who ha ve been diagnosed with hyper tension should be taught \\nthe technique of home BP monit oring, assuming that ther e are no cognitiv e deficiencies that would \\npreclude the technique. A handout about the pur chase and pr oper technique ma y be used. P atients \\nshould pur chase an electr onic, digital home BP cuff. The pr oper cuff siz e should be indicated t o the \\npatient b y the healthcar e provider . Automatic (self-inflating) and non-aut omatic electr onic monit ors ar e \\nequally eff ectiv e, with the non-aut omatic being cheaper but mor e labor intensiv e. \\nPatients should be instructed t o tak e their BP daily , upon awak ening and befor e dinner (other times as \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 21 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 20}),\n",
       " Document(page_content='COPY1. Ensur e that the patient is belie ved to be taking the medication as pr escribed. \\n2. Ensur e that the dose of the medication is adequate. \\n3. Reconsider r eversible causes. \\n4. Add a second drug fr om another class if necessar y to reach goal. necessar y), until the BP is contr olled t o the tar geted r ange discussed abo ve. After BP contr ol is achie ved, \\nBP ma y be obtained monthly . The BP r eadings should be r ecor ded on a BP monit oring sheet and sent or \\nbrought t o the physician. The wrist and finger units, although easy t o use, ar e not r eliable for monit oring \\nblood pr essur e. \\nPrehyper tension. Follow at least annually . \\nStage 1 hyper tension.  Once antihyper tensiv e ther apy is initiated, most patients should r eturn for follow-up \\nand adjustment of medications at monthly inter vals or less until the BP goal is r eached. The eff ect of an \\nantihyper tensiv e agent on BP is typically stabiliz ed in < 2 weeks. A t each visit, BP contr ol, adv erse \\nmedication eff ects, patient adher ence, and new tar get or gan damage should be assessed. If after 1-3 \\nmonths the BP does not r each the tar geted goal: \\nAfter BP is at goal and stable, follow-up visits can usually be at 3- t o 6-month inter vals. A r andomiz ed \\ncontr olled trial showed that for stable patients that patient outcomes wer e equiv alent for follow-up \\ninter vals of 3 and 6 months. No e vidence curr ently exists r egar ding the equiv alence of 6-month and \\n12-month inter vals. Serum potassium and cr eatinine should be monit ored at least annually . Monit oring for \\nmicr oalbuminuria ma y also be useful. \\nStage 2 hyper tension.  Follow-up is gener ally similar t o that for medical ther apy for Stage 1 hyper tension, \\nexcept mor e frequent visits ma y be necessar y, e.g., mor e frequently than monthly inter vals initially t o \\nadequately contr ol BP . \\nAdditional consider ations.  Most patients will r equir e two or mor e medications t o reach goal. Fix ed \\ndosage combination antihyper tensiv e medications ma y simplify ther apy and impr ove adher ence, but \\ngeneric individual agents ar e usually less costly . \\nIf blood pr essur e is uncontr olled after persistent attempts t o do so, or multiple (>3) drugs ar e needed, \\nconsider r eferral to a hyper tension specialist. \\nIntolerance t o multiple medications ma y be an indication of o ver-treated hyper tension due t o a significant \\nwhite coat eff ect. Ambulat ory or home BP monit oring ma y then be helpful. \\nContr olled BP . Once BP is contr olled, office visits e very 3-6 months ar e appr opriate. A t any time, for any \\nstage of hyper tension, consultation with a clinician skilled in the management of hyper tension should be \\nconsider ed if BP cannot be contr olled adequately , patient compliance is poor , or ther e is difficulty \\nidentifying exacerbating conditions or medications. \\nResistant hyper tension. Resistant hyper tension is the failur e to reach goal BP in patients who ar e \\nadhering t o full doses of an appr opriate 3-drug r egimen that includes a diur etic. After ex cluding potential \\nidentifiable causes of hyper tension (T able 5), clinicians should explor e reasons why the patient is not at \\nthe goal BP . Particular attention should be paid t o diur etic type and dose in r elationship t o renal function \\nbecause thiazide-type diur etics lose eff ect once the GFR falls <30 ml/min. Consultation with a \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 22 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 21}),\n",
       " Document(page_content='COPYSpecial Consider ations \\n1. Methyldopa – the drug with the longest experience Pr oblems with this medication include \\nfrequent side eff ects and the need t o dose multiple times a da y. \\n2. Beta-block er with or without diur etic (a voiding atenolol, which ma y be associated with \\nintrauterine gr owth r etardation) – ar e relativ ely popular and the first choice of some. \\n3. Labetalol \\n4. Calcium channel block ers \\nRelated National Guidelines hyper tension specialist should be consider ed if goal BP cannot be achie ved. \\nHyper tension and Pr egnancy . The use of anti-hyper tensiv es in pr egnancy must consider f etal well-being. \\nTreating uncomplicated Stage 1 hyper tension is often not necessar y in other wise low-risk women with \\nnormal r enal function and no other tar get or gan disease. These women should be closely followed during \\npregnancy . Pre-eclampsia or other pr egnancy-induced hyper tension should be tr eated b y a physician \\nexperienced in managing these diseases. \\nWomen considering pr egnancy , who ar e hyper tensiv e and r equir e treatment, should be on anti-\\nhyper tensiv e medication ideally thr ee to six months prior t o conception. Medications for tr eating \\nsignificant hyper tension during pr egnancy , in or der of pr eference, ar e: \\nDiuretics ar e also acceptable t o use. \\nContr aindicated in pr egnancy ar e ACE inhibit ors, ARBs, and r enin inhibit ors. \\nOngoing diabetes scr eening.  While scr eening for diabetes is r ecommended when a mean BP > 135/80 is \\nfirst identified, for patients with hyper tension an optimal inter val for subsequent scr eening for diabetes is \\nnot known. The American Diabetes Association (based on exper t opinion) r ecommends scr eening at \\n3-year inter vals. \\nElderly patients. The benefit of tr eating hyper tension in older adults has been well established. The \\nHYVET study confirmed substantial r eduction in car diovascular risk and mor tality fr om tr eating \\nhyper tension in patients age 80 and older , to a tar get of 150/80 mmHg. \\nNo clear benefit has been shown for syst olic BP tar gets lower than < 150 (e.g., < 140). Lowering diast olic \\nBP to < 65 is a theor etical risk. No clear e vidence exists t o determine the r elativ e risk of achie ving a \\nsystolic BP < 150 if that tr eatment also lowers diast olic BP t o <65. \\nOrthostasis is a common pr oblem in the elderly and monit oring standing and supine BP is impor tant \\nduring tr eatment t o identify this. \\nAntihyper tensiv e choice in the elderly is similar t o other age gr oups. Beta blockade should be a voided \\nunless ther e is a compelling indication such as CAD or CHF . Lower initial antihyper tensiv e drug doses and \\nslower titr ation is gener ally r ecommended. \\nThis guideline is consistent with JNC 7, updated with r esults of major trials subsequently (see \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 23 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 22}),\n",
       " Document(page_content='COPYStrategy for Liter ature Sear ch \\nMeasur es of Clinical P erformance references). It is consistent with the r epor t from the panel members appointed t o JNC 8, ex cept for \\nAfrican Americans without e vidence diabetes or CKD , this guideline r ecommends the same initial drugs as \\nfor other patients without e vidence of diabetes or CKD . \\nPreliminar y evidence was identified using liter ature consider ed relevant in JNC 7 (see annotated \\nreferences). That r epor t utiliz ed liter ature sear ches of the pr eceding r epor ts and added a systematic \\nsear ch of liter ature from Januar y 1997 thr ough April 2003. \\nIn 2007 a sear ch of liter ature from 2003–2007 was per formed that was also utiliz ed to de velop the 2009 \\nversion of this guideline. That sear ch was conducted on Medline pr ospectiv ely using the major k eywor ds \\nof: hyper tension, human adults, English language, clinical trials, guidelines, and published fr om 1/1/03 \\nthrough 5/1/07 . Terms used for specific t opic sear ches within the major k ey wor ds included:  alpha 1 \\nblock er, angiotensin conv erting enzyme inhibit ors, angiotensin II r ecept or antagonist, beta block ers \\n(selectiv e and non-selectiv e), calcium channel block ers (dihy dropyridine and non-  dihydropyridine forms), \\ncentr ally acting alpha-2 agonist, diur etics (thiazide and non-thiazide, loop, potassium-sparing), v asodilat or \\n(direct), a voidance (alcohol, str ess, t obacco), blood pr essur e monit oring (ambulat ory, home), dietar y \\n(caff eine, calcium, garlic, magnesium, onion, potassium, sodium), ex ercise, disease-based management \\n(stroke, cor onar y artery disease, car diac, hear t failur e, ar terial fibrillation, peripher al vascular disease, \\ndiabetes, chr onic kidne y disease, metabolic syndr ome), and r esistant hyper tension..  Detailed sear ch terms \\nand str ategy a vailable upon r equest. \\nIn 2013 the full liter ature sear ch was def erred while waiting for the sear ch results of JNC 2013 (\"JNC 8\"). \\nHowe ver, exper t member of the team identified thr ee topics for which impor tant new e vidence had been \\npublished and systematic sear ches wer e per formed on those t opics. The sear ch was conducted on \\nMedline pr ospectiv ely using the major k eywor ds of: hyper tension, human adults, English language, \\nguidelines, clinical trials, cohor t studies, and published fr om 1/1/03 thr ough 6/1/13 . Terms used for \\nspecific t opic sear ches within the major k ey wor ds included:  combination of \\' ACE (angiotensin conv erting \\nenzyme) inhibit ors and ARB (angiotensin r ecept or block ers), combination of ARB and DRI (dir ect r enin \\ninhibit ors), and patients age ≥ 65 y ears (older/elderly) and tar get blood pr essur e and tr eatment. \\nThe sear ch was conducted in components each k eyed to a specific causal link in a formal pr oblem \\nstructur e (available upon r equest). The sear ch was supplemented with v ery recent information a vailable \\nto exper t members of the panel, including abstr acts fr om r ecent meetings and r esults of clinical trials. \\nNegativ e trials wer e specifically sought. The sear ch was a single cy cle. Conclusions wer e based on \\nprospectiv e randomiz ed clinical trials if a vailable, t o the ex clusion of other data; if r andomiz ed contr olled \\ntrials wer e not a vailable, obser vational studies wer e admitted t o consider ation. If no such data wer e', metadata={'source': './mm_htn_guidelines.pdf', 'page': 23}),\n",
       " Document(page_content='The sear ch was conducted in components each k eyed to a specific causal link in a formal pr oblem \\nstructur e (available upon r equest). The sear ch was supplemented with v ery recent information a vailable \\nto exper t members of the panel, including abstr acts fr om r ecent meetings and r esults of clinical trials. \\nNegativ e trials wer e specifically sought. The sear ch was a single cy cle. Conclusions wer e based on \\nprospectiv e randomiz ed clinical trials if a vailable, t o the ex clusion of other data; if r andomiz ed contr olled \\ntrials wer e not a vailable, obser vational studies wer e admitted t o consider ation. If no such data wer e \\navailable for a giv en link in the pr oblem formulation, exper t opinion was used t o estimate eff ect siz e. \\nNational pr ograms that ha ve clinical per formance measur es for car e for hyper tension include the \\nfollowing. \\nCenters for Medicar e & Medicaid Ser vices: \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 24 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 23}),\n",
       " Document(page_content=\"COPY• Physician Quality Repor ting Measur es for Gr oup Pr actice Repor ting Option (GPRO) \\n• Clinical Quality Measur es for financial incentiv es for Meaningful Use of cer tified Electr onic \\nHealth Recor d technology (MU) \\n• Quality measur es for Accountable Car e Organizations (A CO) \\nDisclosur es These pr ogram's clinical per formance measur es for hyper tension ar e summariz ed below . When pr ograms \\nhave measur es, the measur es ar e gener ally similar , although specific details v ary (e.g., population \\ninclusions and ex clusions). \\nBlood pr essur e measur ement.  The per centage of patient visits for patients aged 18 y ears or older with a \\ndiagnosis of hyper tension who ha ve been seen for at least 2 office visits, with blood pr essur e recor ded. \\n(MU, A CO, GRPO) \\nContr olling high blood pr essur e. The per centage of patients aged 18–85 y ears with a diagnosis of \\nhyper tension and whose blood pr essur e was adequately contr olled (< 140/90) (MU, A CO, GRPO) \\nHyper tension: Impr ovement in blood pr essur e. The per centage of patients aged 18-85 y ears with a \\ndiagnosis of hyper tension whose blood pr essur e impr oved during the measur ement period (MU, A CO, \\nGPRO) \\nPreventiv e car e and scr eening: Scr eening for high blood pr essur e and follow-up documented . \\nPercentage of patients aged 18 y ears and older seen during the r epor ting period who wer e scr eened for \\nhigh blood pr essur e AND a r ecommended follow-up plan is documented based on the curr ent blood \\npressur e reading (MU, A CO) \\nAdditional measur es regar ding car e for hyper tension exist for patients with specific medical conditions, \\ne.g., diabetes, cor onar y artery disease. \\nUniv ersity of Michigan Health System endorses the Guidelines of the Association of American Medical \\nColleges and the Standar ds of the Accr editation Council for Continuing Medical E ducation that the \\nindividuals who pr esent educational activities disclose significant r elationships with commer cial \\ncompanies whose pr oducts or ser vices ar e discussed. Disclosur e of a r elationship is not intended t o \\nsuggest bias in the information pr esented, but is made t o provide r eaders with information that might be \\nof potential impor tance t o their e valuation of the information. \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 25 of 30\", metadata={'source': './mm_htn_guidelines.pdf', 'page': 24}),\n",
       " Document(page_content=\"COPYTeam Member Relationship Company \\nMichael P . Dorsch, \\nPharmD Speak er's \\nBureau Astra Zeneca, \\nBoehringer \\nIngelheim, \\nJansen \\nMark W . Ealo vega, MD (none)  \\nR. Van Harrison, PhD (none)  \\nKenneth Jamerson, MD Consultant \\nSpeak er's Bur eau \\nResear ch Suppor t Astra /Zeneca, \\nBoehringer \\nIngelheim, \\nNovartis, T akeda \\nDaiichi Sanko, Merk \\nNovartis \\nMasahit o Jimbo, MD (none)  \\nReview and Endorsement \\nAcknowledgements \\nReferences Drafts of this guideline wer e reviewed in clinical conf erences and b y distribution for comment within \\ndepar tments and divisions of the Univ ersity of Michigan Medical School t o which the content is most \\nrelevant: F amily Medicine, Gener al Medicine, and Car diology . The final v ersion was endorsed b y the \\nClinical Pr actice Committee of the Univ ersity of Michigan F aculty Gr oup Pr actice and the Ex ecutiv e \\nCommittee for Clinical Affairs of the Univ ersity of Michigan Hospitals and Health Centers. \\nThe following individuals ar e acknowledged for their contributions t o previous v ersions of this guideline. \\n1997:Ste ven Y arows, MD , FACP, William Barrie, MD , Christine Birmingham, RN, Ste ven Erickson, PharmD , \\nKenneth Jamerson, MD , Christ opher Wise, PhD , Philip Zaz ove, MD . \\n2003:William Barrie, MD , Janice Stumpf, PharmD , Kenneth Jamerson, MD , Philip Zaz ove, MD; Lee Gr een, \\nMD (consultant). \\n2009: Masahit o Jimbo, MD , William E. Barrie, MD , Michael P Dorsch, PharmD , R V an Harrison, PhD , \\nKenneth A. Jamerson, MD . \\nThe A CCORD Study Gr oup. E ffects of intensiv e blood-pr essur e contr ol in T ype 2 diabetes mellitus. NEJM, \\n2010; 362: 1575-1585. \\nThe ALLH AT Officers and Coor dinat ors for the ALLH AT Collabor ative Resear ch Gr oup. Major Outcomes in \\nHigh Risk Hyper tensiv e Patients Randomiz ed to Angiotensin-Conv erting Enzyme Inhibit or or calcium \\nBlock er vs Diur etic: The Antihyper tensiv e and Lipid-Lowering T reatment t o Prevent Hear t Attack T rail \\n(ALLH AT). J AMA 288:2981-2997, 2002. \\nAronow WS, Fleg JL, P epine CJ, et al. A CCF/AH A 2011 exper t consensus document on hyper tension in \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 26 of 30\", metadata={'source': './mm_htn_guidelines.pdf', 'page': 25}),\n",
       " Document(page_content='COPYthe elderly . Journal of the American College of Car diology , 2011; 57(20): 2037-2114. \\nBeck ett NS, P eters R, Fletcher AE, et al. T reatment of hyper tension in patients 80 y ears of age or older . \\n(HYVET study .) NEJM, 2008; 358: 1887-1898. \\nBrown MJ, McInnes GT , Papst CC, Zhang J, MacDonald TM. Aliskir en and the calcium channel block er \\namlodipine combination as an initial tr eatment str ategy for hyper tension contr ol (A CCELERA TE): a \\nrandomised, par allel-gr oup trial. Lancet 2011; 377: 312-320. \\nDenar do SJ, Gong Y , Nichols WW , et al. Blood pr essur e and outcomes in v ery old hyper tensiv e cor onar y \\nartery disease patients: An INVEST substudy . American Journal of Medicine, 2010; 123(8):719-726. \\nHansson L. Lindholm LH. Ekbom T . Dahlof B. Lank e J. Schersten B. W ester PO . Hedner T . de F aire U. \\nRandomised trial of old and new antihyper tensiv e drugs in elderly patients: car diovascular mor tality and \\nmorbidity the Swedish T rial in Old P atients with Hyper tension-2 study , Lancet. 354(9192):1751-6, 1999 \\nNov 20 \\nHansson L. Zanchetti A. Carruthers SG. Dahlof B. Elmf eldt D . Julius S. Menar d J. Rahn KH. W edel H. \\nWesterling S. E ffects of intensiv e blood-pr essur e lowering and low-dose aspirin in patients with \\nhyper tension: principal r esults of the Hyper tension Optimal T reatment (HO T) randomiz ed trial. HO T Study \\nGroup, Lancet. 351(9118):1755-62, 1998 Jun 13. \\nThe Hear t Outcomes Pr evention E valuation Study Inv estigat ors. E ffects of an angiotensin-\\nconv erting–enzyme inhibit or, Ramipril, on car diovascular e vents in high-risk patients, N Engl J Med 2000; \\n342:145-153, Jan 20, 2000 \\nJamerson K, W eber M A, Bakris GL et al for the A CCOMPLISH T rial Inv estigat ors. Benaz epril plus \\namlodipine or hy drochlor othiazide for hyper tension in high-risk patients. NEJM, 2008; 359: 2417-2428. \\nJames P A, Oparil S, Car ter BL, et al. 2014 e vidence-based guideline for the management of high blood \\npressur e in adults: Repor t from the panel members appointed t o the eight Joint National Committee (JNC \\n8). J AMA, doi: 10.1001/jama.2013.284427. Published online Dec. 18, 2013. \\nLasagna L. Diur etics vs alpha-block ers for tr eatment of hyper tension: lessons fr om ALLH AT. \\nAntihyper tensiv e and Lipid-Lowering T reatment t o Prevent Hear t Attack T rial, J AMA. 283(15):2013-4, 2000 \\nApr 19. \\nLindholm LH, Carlber g B, Samuelsson O . Should [beta] block ers r emain first choice in the tr eatment of \\nprimar y hyper tension? A meta-analysis. The Lancet, 2005; 366 (9496):1545-1552. \\nONTARGE T Inv estigat ors, Y usuf S, T eo KK, P ogue J, Dy al L, Copland I, Schumacher H, Dagenais G, Sleight \\nP, Anderson C. T elmisar tan, r amipril, or both in patients at high risk for v ascular e vents. N Engl J Med. \\n2008 Apr 10;358(15):1547-59.', metadata={'source': './mm_htn_guidelines.pdf', 'page': 26}),\n",
       " Document(page_content='Apr 19. \\nLindholm LH, Carlber g B, Samuelsson O . Should [beta] block ers r emain first choice in the tr eatment of \\nprimar y hyper tension? A meta-analysis. The Lancet, 2005; 366 (9496):1545-1552. \\nONTARGE T Inv estigat ors, Y usuf S, T eo KK, P ogue J, Dy al L, Copland I, Schumacher H, Dagenais G, Sleight \\nP, Anderson C. T elmisar tan, r amipril, or both in patients at high risk for v ascular e vents. N Engl J Med. \\n2008 Apr 10;358(15):1547-59. \\nParving HH, Br enner BM, McMurr ay JJ, de Z eeuw D , Haffner SM, Solomon SD , Chatur vedi N, P ersson F , \\nDesai AS, Nicolaides M, Richar d A, Xiang Z, Brunel P , Pfeffer M A; AL TITUDE Inv estigat ors. Car diorenal end \\npoints in a trial of aliskir en for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13. \\nPfeffer M A, Swedber g CB, Held P , et al. E ffects of candesar tan on mor tality and morbidity in patient with \\nchronic hear t failur e: the CH ARM-Ov erall pr ogramme. Lancet 2003; 362:759. \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 27 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 26}),\n",
       " Document(page_content='COPYHyper tension Guideline T eam \\nAPPENDI X. Standar dized Blood Pr essur e \\nMeasur ement \\n• Aneroid manometer could be used. Howe ver, the deflated cuff should r ead exactly z ero, and it \\nshould be calibr ated at least y early , unless used fr equently and then y early . \\n• Electr onic manometers  should be calibr ated twice a y ear if used weekly , or once a y ear if used \\nless often. \\n• The cuff should be the appr opriate siz e for the measur ed arm, and each cuff should ha ve Podymow T , August P . Update on the use of antihyper tensiv e drugs in pr egnancy . Hyper tension \\n2008;51:960-969. \\nThe 7th r epor t of the Joint National Committee on Pr evention, Detection, E valuation, and T reatment of \\nHigh Blood Pr essur e. Hyper tension, 2003; 42:1206. Complete r epor t: NHLBI, 2004, NIH Publication No \\n04-5230. \\nTeam lead \\nMasahit o Jimbo, MD , Family Medicine \\nTeam members \\nMichael P Dorsch, PharmD , Pharmacy \\nMark W Ealo vega, MD , Gener al Medicine \\nR Van Harrison, PhD , Medical E ducation \\nKenneth A Jamerson, MD , Cardiovascular Medicine \\nAmbulat ory Clinical Guidelines Ov ersight \\nGrant M Gr eenber g, MD , MA, MHSA \\nR Van Harrison, PhD \\nInitial Release \\n Februar y 1997 \\nMost Recent Major Update \\n May 2014 \\nInterim/Minor Re vision \\n July 2019 \\n© Regents of the Univ ersity of Michigan \\nThese guidelines should not be construed as including all pr oper methods of car e or ex cluding other \\nacceptable methods of car e reasonably dir ected t o obtaining the same r esults.   The ultimate judgment \\nregar ding any specific clinical pr ocedur e or tr eatment must be made b y the physician in light of the \\ncircumstances pr esented b y the patient. \\nTypes of Measuring De vices \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 28 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 27}),\n",
       " Document(page_content=\"COPY\\nAppr oval Signatur es \\nStep Description Approver Date mark ers t o note the pr oper selection. \\n1. Prior activity . Ideally , the patient should  not have: \\n• within 30 minutes – smok ed, ingested caff eine, or ex ercised \\n• within 2 hours – eaten or ingested alcohol \\n2. Prepar ation. The patient should sit with their back suppor ted and f eet on the floor (not seated \\non the exam table) for 5 minutes befor e the 1st blood pr essur e is tak en. \\n3. First visit: bilater al measur es. The blood pr essur e should be measur ed at least once in each \\narm (at the patient' s first visit) t o assur e that ther e is no diff erence in blood flow (i.e., should be \\n< 10 mm Hg diff erence), and if ther e is a significant diff erence, the higher pr essur e should be \\nused ther eafter . \\n4. Cuff. Impr oper cuff siz e is the most common sour ce of measur ement err or. The arm should be \\nbare, and the cuff should be fitted secur ely so that the bladder midline is o ver the br achial ar tery \\nand the lower edge of the cuff is 1 inch abo ve the antecubital fossa. \\n5. Gauge. The gauge should be at e ye level. \\n6. Arm. The patient' s arm should be suppor ted, and the stethoscope or measur ement point should \\nbe at hear t level. \\n7. Inflation. Inflate the cuff at least 30 mm Hg abo ve the syst olic r eading and deflate at a \\nmaximum of 2-3 mm per second or a maximum of 2 mm per pulse beat between the K orotkoff \\nsounds. \\n8. Measur ement. Recor d the syst olic r eading at the first sound hear d Korotkoff phase I and the \\ndiast olic r eading as the last sound hear d Korotkoff phase V . If ther e is a muffling of the sound, \\nthis should also be r ecor ded K orotkoff phase IV (e.g. - 150/50/0). \\n9. Repeated measur ement. Take the patient' s pulse while waiting t o repeat a second \\nmeasur ement after 1-2 minutes. If the measur ement is per formed immediately after walking \\ninto the r oom and the r eading is normal, it should be r ecor ded and r epeated in 1-2 minutes. If \\nthe blood pr essur e is ele vated immediately after walking int o the r oom, it should not be \\nrecor ded and the blood pr essur e should be r epeated after 5 minutes of r est. A t least two \\nreadings should be tak en, and if the r eadings v ary by mor e than 5 mm Hg diast olic, the r eadings \\nshould be r epeated until ther e is less v ariability . \\n10. Other r ecor ded information. The arm used, position of the patient, and the siz e of the cuff \\n(when non-standar d cuff siz e used) should be r ecor ded. \\n11. Inform. Inform the patient of the r eadings. Proper T echnique \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 29 of 30\", metadata={'source': './mm_htn_guidelines.pdf', 'page': 28}),\n",
       " Document(page_content='COPYQuality Re view April Pr oudlock: Pr oject Senior \\nManager 08/2021 \\nQuality Re view Ellen P atrick: Admin Specialist \\nIntermediate 05/2020 \\nOwner Ellen P atrick: Admin Specialist \\nIntermediate 05/2020 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 30 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 29})]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "35"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from langchain.prompts.prompt import PromptTemplate\n",
    "# prompt_template = \"\"\"You are a clinical practice guideline expert. A healtcare professional will ask you a question pertaining to medical guidelines, and you will provide a helpful answer. Please do not recommended speaking to a healtcare professional as part of your answer. If you don't know the answer, just say that you don't know. Use the following context from the medical guidelines to answer the question:\n",
    "# {context}\n",
    "# Question: {question}\n",
    "# \"\"\"\n",
    "# QA_PROMPT = PromptTemplate(template=prompt_template, input_variables=[\"context\", \"question\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "# create embedding\n",
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "embeddings = OpenAIEmbeddings()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.vectorstores import FAISS\n",
    "faiss_db = FAISS.from_documents(documents, embeddings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='COPYpropranolol Inder al LA   40 mg \\nBID 80 mg BID $4-5 $150-300 \\nInder al XL  60 mg daily 80 mg \\ndaily 120 mg \\ndaily $27-54 $178-356 \\nlabetalol Trandate/\\nNormodyne  100 mg BID 200 mg \\nBID 300 mg \\nBID $24-41 $40-69 \\nnadolol Corgard  40 mg daily 80 mg \\ndaily 160 mg \\ndaily $96-153 $127-350 \\nmetoprolol tar trate Lopr essor   50 mg \\nBID 100 mg \\nBID $11-15 $134-268 \\nmetoprolol \\nsuccinate Toprol XL   100 mg \\ndaily 200 mg \\ndaily $27-45 $58-93 \\nByst olic  2.5 mg daily 10-20 \\nmg \\ndaily 40 mg \\ndaily  $78-159 \\nnebiv olol Coreg  3.125 BID 12.5-25 \\nmg BID 25 BID $6-7 $90-160 \\ncarvedilol Coreg CR 10mg \\ndaily 20 mg daily 40 mg \\ndaily 80 mg \\ndaily n/a $158 all \\nDirect V asodilat ors \\nHydralazine generic  25 mg TID 50 mg \\nTID 100 mg \\nTID $10-25 n/a \\nmino xidil generic   5mg \\nBID 20mg BID $11-28 n/a \\nCentr ally-acting alpha-2 agonists \\nclonidine Catapr es   0.1 TID 0.3 TID $8 all $180-275 \\nMethyldopa generic  25 0mg TID 500 mg \\nTID 1000 mg \\nTID $20-42 n/a \\nAlpha Block ers \\nDoxazosin Cardura  1mg daily 2mg \\ndaily 4mg daily $17-24 $66-70 \\nterazosin Hytrin  1mg daily 2mg \\ndaily 5mg daily $4-5 $42-43 \\nPrazosin Minipr ess  1mg BID 2mg \\nBID 5mg BID $17-33 $68-160 \\nRenin Inhibit ors \\naliskir en Tekturna   150 mg \\ndaily 300mg \\ndaily n/a $112-142 \\nOther Diur etics \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 10 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 9}),\n",
       " Document(page_content='COPYlisinopril/HC TZ Prinzide/\\nZestoretic 10 mg/\\n12.5 mg \\ndaily 20 mg/12.5 mg daily 20 mg/25 \\nmg daily $4-5 $45 all \\nfosinopril/HC TZ Monopril \\nHCT  10 mg/12.5 mg daily 20 mg/\\n12.5 mg \\ndaily $38 all $42 \\nquinapril/HC TZ Accur etic 10 mg/\\n12.5 mg \\ndaily 20 mg/12.5 mg daily 20 mg/25 \\nmg daily $23 all $79-96 \\nAngiotensin Recept or Block ers \\ntelmisar tan Micar dis  40 mg daily 80 mg \\ndaily $116 all $145 all \\nolmesar tan Benicar  20 mg daily 40 mg \\ndaily n/a $115-160 \\nvalsar tan Diovan 80 mg \\ndaily 160 mg daily 320 mg \\ndaily n/a $127-136 \\nirbesar tan Avapro  150 mg daily 300 mg \\ndaily $12-15 $92-111 \\ncandesar tan Atacand 8 mg \\ndaily 16 mg daily 32 mg \\ndaily $86-107 $95-128 \\neprosar tan Teveten 50 mg \\ndaily 400 mg daily 600 mg \\ndaily $98 $125 \\nlosar tan Cozaar  100 mg daily 50 mg BID $6-12 $113-156 \\nazilsar tan Edarbi  40 mg daily 80 mg \\ndaily n/a $132 \\nAngiotensin Recept or Block er / Diur etic Combinations \\nvalsar tan/HC TZ Diovan \\nHCT 40 mg/\\n12.5 mg \\ndaily 80 mg/12.5 mg daily 160 mg/\\n12.5 mg \\ndaily $16 all $120-142 \\ntelmisar tan/HC TZ Micar dis \\nHCC  80 mg/12.5 mg daily 80 mg/25 \\nmg daily n/a $145 all \\ncandesar tan/HC TZ Atacand \\nHCT  16 mg/12.5 mg daily 32 mg/\\n12.5 mg \\ndaily $60-63 $125 all \\nlosar tan/HC TZ Hyzaar  50 mg/12.5 mg daily 100 mg/\\n25 mg \\ndaily $6-8 $92-118 \\nolmesar tan/HC TZ Benicar \\nHCT 20 mg/\\n12.5 mg \\ndaily 40 mg/12.5 mg daily 40 mg/25 \\nmg daily n/a $160 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 8 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 7}),\n",
       " Document(page_content='COPYeprosar tan/HC TZ Teveten \\nHCT  600 mg/12.5 mg \\ndaily 600 mg/\\n25 mg \\ndaily n/a $132 \\nazilsar tan/C TD Edarb yclor  40 mg/ 12.5mg daily 40 mg/25 \\nmg daily n/a $120 \\nCalcium Channel Block ers \\nNon-DHP \\nverapamil SR Calan SR       \\ndiltiaz em Cardizem 30 mg \\nQID 60 mg TID  60 mg \\nQID 90 mg TID $6 $104 \\ndiltiaz em CD Cardizem \\nCD \\nDilacor 120 mg \\ndaily 180 mg daily 240 mg \\ndaily 300 mg \\ndaily $20-32 $328-554 \\nDHP  (dihy dropyridines) \\namlodipine Norvasc   5 mg \\ndaily 10 mg \\ndaily $2-4 $96-131 \\nfelodipine Plendil   5 mg \\ndaily 10 mg \\ndaily $19-29 $41-73 \\nnifedipine CC Adalat CC \\nProcar dia \\nXL  30 mg daily 60 mg \\ndaily 90 mg \\ndaily $15-28 $106-203 \\nnisoldipine Sular  20 mg daily 30 mg \\ndaily 40 mg \\ndaily $239-260 $429 \\nisradipine CR Dynacir c \\nCR   5 mg \\ndaily 10 mg \\ndaily $64-85 n/a \\nCalcium Channel Block er / A CE Inhibit or Combinations \\namlodipine/\\nbenaz epril Lotrel 2.5mg/10mg daily 5mg/\\n10mg \\ndaily 5mg/\\n20mg \\ndaily $10-21 $155-158 \\ntrandolapril/\\nverapamil Tarka 1mg/\\n240mg 2mg/180mg 2mg/\\n240mg 4mg/\\n240m all \\ndaily n/a $125 all \\nAldoster one A ntagonists \\nspironolact one Aldact one   25 mg \\ndaily 50 mg \\ndaily $12-18 $69-116 \\nepler enone Inspr a   50 mg \\ndaily 50 mg BID $54-128 $176-352 \\nBeta Block ers \\natenolol Tenormin  25 mg daily 50 mg \\ndaily 100 mg \\ndaily $4-5 $50-77 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 9 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 8}),\n",
       " Document(page_content='COPYDrug Class \\n(generic name) Brand \\nName Usual Dosage Regimens 30 Da y Cost* \\nGeneric Brand \\nThiazide Diur etics \\nhydrochlor othiazide generic  12.5mg.daily 25mg \\ndaily 50 mg \\ndaily $4 n/a \\nchlor thalidone generic    25 mg \\ndaily $21 n/a \\nPotassium Sparing/Thiazide Combination Diur etics \\namiloride /HC TZ** generic   5 mg/50 mg daily $12 n/a \\ntriamter ene/HC TZ generic   37.5 mg/25 mg \\ndaily $11 n/a \\nspironolact one/\\nHCTZ generic   25 mg/25 mg daily $28 $43 \\nACE Inhibit ors \\ncapt opril Capoten  12.5 mg BID 25 mg \\nBID 50 mg TID $23-40 n/a \\nbenaz epril Lotensin 5 mg \\ndaily 10 mg daily 20 mg \\ndaily 40 mg \\ndaily $5 all $62 all \\nquinapril Accupril  10 mg daily 20 mg \\ndaily 40 mg \\ndaily $9 all $75 all \\nlisinopril Prinivil/\\nZestril 5 mg \\ndaily 10 mg daily 20 mg \\ndaily 40 mg \\ndaily $4-5 $42-67 \\nenalapril Vasotec 2.5 mg \\ndaily 5 mg daily 10 mg \\ndaily 10 mg BID $7-11 $107-272 \\nfosinopril Monopril  10 mg daily 20 mg \\ndaily 40 mg \\ndaily $8 all n/a \\ntrandolapril Mavik  1 mg daily 2 mg \\ndaily 4 mg daily $16 all $52 all \\nmoexipril Univ asc   7.5 mg \\ndaily 15 mg \\ndaily $18-30 $84-88 \\nramipril Altace  2.5 mg daily 5 mg \\ndaily 10 mg \\ndaily $6-7 $92-113 \\nperindopril Aceon   4 mg \\ndaily 8 mg daily 20-22 $79-96 \\nACE Inhibit or / Diur etic Combinations \\nbenaz epril/HC TZ Lotensin \\nHCT 5 mg/\\n6.25 mg \\ndaily 10 mg/12.5 mg daily 20 mg/\\n12.5mg \\ndaily $15 $56 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 7 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 6})]"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain.chains.question_answering import load_qa_chain\n",
    "query = \"What is the 90-day cost for metoprolol?\"\n",
    "faiss_db.similarity_search(query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.vectorstores import Chroma\n",
    "\n",
    "chroma_db = Chroma.from_documents(\n",
    "    documents=documents, \n",
    "    embedding=embeddings, \n",
    "    persist_directory=\"db\"\n",
    ")\n",
    "# call persist() to ensure the embeddings are written to disk. This isn't necessary in a script - the \n",
    "# database will be automatically persisted when the client object is destroyed.\n",
    "chroma_db.persist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: faiss-cpu in ./myenv/lib/python3.11/site-packages (1.7.4)\n"
     ]
    }
   ],
   "source": [
    "# !pip install faiss-cpu\n",
    "# !pip freeze > requirements.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains.question_answering import load_qa_chain\n",
    "from langchain.llms import OpenAI\n",
    "def qa_doc(query, docsearch):\n",
    "    chain = load_qa_chain(OpenAI(), chain_type=\"stuff\")\n",
    "    docs = docsearch.similarity_search(query)\n",
    "    chain.run(input_documents=docs, question=query)\n",
    "    print(\"chain:\", chain)\n",
    "    print(\"docs\", docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "chain: memory=None callbacks=None callback_manager=None verbose=False tags=None metadata=None input_key='input_documents' output_key='output_text' llm_chain=LLMChain(memory=None, callbacks=None, callback_manager=None, verbose=False, tags=None, metadata=None, prompt=PromptTemplate(input_variables=['context', 'question'], output_parser=None, partial_variables={}, template=\"Use the following pieces of context to answer the question at the end. If you don't know the answer, just say that you don't know, don't try to make up an answer.\\n\\n{context}\\n\\nQuestion: {question}\\nHelpful Answer:\", template_format='f-string', validate_template=True), llm=OpenAI(cache=None, verbose=False, callbacks=None, callback_manager=None, tags=None, metadata=None, client=<class 'openai.api_resources.completion.Completion'>, model_name='text-davinci-003', temperature=0.7, max_tokens=256, top_p=1, frequency_penalty=0, presence_penalty=0, n=1, best_of=1, model_kwargs={}, openai_api_key='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', openai_api_base='', openai_organization='', openai_proxy='', batch_size=20, request_timeout=None, logit_bias={}, max_retries=6, streaming=False, allowed_special=set(), disallowed_special='all', tiktoken_model_name=None), output_key='text', output_parser=NoOpOutputParser(), return_final_only=True, llm_kwargs={}) document_prompt=PromptTemplate(input_variables=['page_content'], output_parser=None, partial_variables={}, template='{page_content}', template_format='f-string', validate_template=True) document_variable_name='context' document_separator='\\n\\n'\n",
      "docs [Document(page_content='COPYDrug Class \\n(generic name) Brand \\nName Usual Dosage Regimens 30 Da y Cost* \\nGeneric Brand \\nThiazide Diur etics \\nhydrochlor othiazide generic  12.5mg.daily 25mg \\ndaily 50 mg \\ndaily $4 n/a \\nchlor thalidone generic    25 mg \\ndaily $21 n/a \\nPotassium Sparing/Thiazide Combination Diur etics \\namiloride /HC TZ** generic   5 mg/50 mg daily $12 n/a \\ntriamter ene/HC TZ generic   37.5 mg/25 mg \\ndaily $11 n/a \\nspironolact one/\\nHCTZ generic   25 mg/25 mg daily $28 $43 \\nACE Inhibit ors \\ncapt opril Capoten  12.5 mg BID 25 mg \\nBID 50 mg TID $23-40 n/a \\nbenaz epril Lotensin 5 mg \\ndaily 10 mg daily 20 mg \\ndaily 40 mg \\ndaily $5 all $62 all \\nquinapril Accupril  10 mg daily 20 mg \\ndaily 40 mg \\ndaily $9 all $75 all \\nlisinopril Prinivil/\\nZestril 5 mg \\ndaily 10 mg daily 20 mg \\ndaily 40 mg \\ndaily $4-5 $42-67 \\nenalapril Vasotec 2.5 mg \\ndaily 5 mg daily 10 mg \\ndaily 10 mg BID $7-11 $107-272 \\nfosinopril Monopril  10 mg daily 20 mg \\ndaily 40 mg \\ndaily $8 all n/a \\ntrandolapril Mavik  1 mg daily 2 mg \\ndaily 4 mg daily $16 all $52 all \\nmoexipril Univ asc   7.5 mg \\ndaily 15 mg \\ndaily $18-30 $84-88 \\nramipril Altace  2.5 mg daily 5 mg \\ndaily 10 mg \\ndaily $6-7 $92-113 \\nperindopril Aceon   4 mg \\ndaily 8 mg daily 20-22 $79-96 \\nACE Inhibit or / Diur etic Combinations \\nbenaz epril/HC TZ Lotensin \\nHCT 5 mg/\\n6.25 mg \\ndaily 10 mg/12.5 mg daily 20 mg/\\n12.5mg \\ndaily $15 $56 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 7 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 6}), Document(page_content='COPY\\n• Once daily administr ation \\n• Reduction in CV complications demonstr ated in clinical trials \\n• Choice of agent(s) that also tr eat concurr ent conditions \\n• Least potential disruptiv e side-eff ects based on concurr ent conditions or lif estyles \\n• Least expensiv e (both in pharmaceutical and labor atory monit oring costs) \\n• Fixed combination ther apy can be mor e cost-eff ectiv e and ma y impr ove compliance. Some \\npatients ma y benefit fr om beginning with fix ed combination ther apy (e.g., Stage 2 hyper tension \\nor patients r esistant t o monother apy in the past). Adequate physical activity . Regular aer obic physical activity ma y be beneficial for both pr evention and \\ntreatment of hyper tension. It ma y enable weight loss, impr ove functional health status, and diminish \\nmortality and risk for car diovascular disease. Thir ty to for ty-fiv e minutes of brisk walking thr ee or four \\ntimes weekly is adequate and eff ectiv e. Resistiv e isot onic activities as sole ex ercise ar e not \\nrecommended t o lower BP in hyper tensiv e patients. \\nTobacco a voidance . All smok ers should be off ered assistance in smoking cessation and str ongly advised \\nto quit. \\nPotassium . High dietar y potassium ma y protect against hyper tension de velopment. Hypokalemia ma y \\nexacerbate hyper tension and induce v entricular arrhythmia. P otassium sparing diur etics and A CE \\ninhibit ors r etain potassium and magnesium wher eas simple potassium chloride r eplacement does not \\nreplace magnesium. \\nOther dietar y fact ors. Calcium supplementation ma y result in a v ery small r eduction in BP (syst olic -1.27 \\nmm Hg; diast olic -0.24 mm Hg). No definitiv e data suggest magnesium supplementation lowers blood \\npressur e. Dietar y fats ha ve no eff ect on blood pr essur e. Acute caff eine ingestion ma y ele vate BP; \\nhowe ver, tachyphylaxis t o chr onic ingestion attenuates this eff ect. A diet low in sodium and satur ated \\nfats, and high in v egetables, fruits, and low fat dair y products has been shown t o lower blood pr essur es \\n(the \"D ASH\" diet). \\nDrug ther apy. Hyper tension is a chr onic disease. Thus, the choice of which medication(s) t o prescribe has \\nlong term implications. \\nDrug selection.  Data fr om a v ery large multicenter RC T suppor ted b y smaller studies demonstr ate that \\nmoder ate-t o-high dose thiazide diur etics (chlor thalidone 25 mg/da y) ar e as good as any other class of \\nagents in r educing car diovascular adv erse outcomes, and superior in secondar y outcomes such as str oke \\nand CHF . Most patients will r equir e two or mor e drugs t o achie ve contr ol, and a f ew will not t olerate \\nthiazides. The choice of additional or alternativ e medication should be individualiz ed to achie ve the tar get \\nBP and the following goals: \\nAll agents within  a class ha ve similar physiological action, ex cept calcium channel block ers and beta \\nblock ers, which ha ve sub-classes with diff erent physiological eff ects.  If monother apy is not eff ectiv e in \\nreaching the BP goal, the addition or substitution of a diff erent class with diff erent physiological action is \\nindicated. Combining medications fr om the same class is not eff ectiv e. Table 2 shows costs of drug \\ntreatment for v arious antihyper tensiv e agents. \\nDiuretics, beta block ers, A CE inhibit ors, and long-acting dihy dropyridine CCBs ha ve been shown in \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/\\npolicy/8093105/. Copyright © 2023 Michigan Medicine PublicPage 17 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 16}), Document(page_content='COPY(HTN) pr ovides significant impr ovements in clinical outcomes  [IA]. Recommended BP \\ntargets ar e syst olic blood pr essur e of < 140 mmHg ( [IB] for CHF and CAD; [ID] for \\ndiabetes and other end or gan damage)  and diast olic BP goal of < 90 mmHg [IB]. \\n◦ Treatment of SBP o ver 160 mmHg is impor tant in r educing CV A and CHF risk [IA]. \\n◦ Lifestyle modifications t o lower BP ar e impor tant adjuncts t o drug ther apy [IA]. \\n◦ Begin ther apy with a thiazide diur etic, A CE inhibit or, or long-acting dihy dropyridine \\ncalcium channel block er for almost all patients. Add second and thir d agents as \\nneeded t o achie ve eff ectiv e BP r eduction goals [IA]. \\n▪ Specific illnesses ma y guide the initial and subsequent choice of agents, \\ne.g.: \\n▪ ACE inhibit ors (ARB for those unable t o tolerate A CE inhibit ors) \\nfor patients with r enal disease, diabetes with either micr o- or \\nmacr oalbuminuria, or L V dysfunction \\n▪ Beta-block ers for those with CAD or CHF . \\n▪ Over 70% of individuals r equir e two or mor e drugs t o achie ve BP goals. A \\nfixed combination ther apy ma y be cost-eff ectiv e. Once a da y medications \\nincrease compliance and ar e preferred. \\nClinical Back ground \\nClinical Pr oblem  and Management Issues * Str ength of r ecommendation: \\nI= gener ally should be per formed; II = ma y be r easonable t o per form; III = gener ally should not be \\nperformed. \\nLevels of e vidence for the most significant r ecommendations \\nA = r andomiz ed contr olled trials; B=contr olled trials, no r andomization; C=obser vational trials; D=opinion \\nof exper t panel \\nIncidence \\nForty-thr ee million United States adults ha ve hyper tension, r epresenting 24% of the U.S. adult population; \\n20 million ha ve no medication pr escribed, and 12 million ar e on medication but not contr olled. Thus, \\nabout one out of four hyper tensiv e patients ar e adequately contr olled. Uncontr olled hyper tension r esults \\nin end stage or gan damage, which leads t o significant mor tality and morbidity . \\nTable 1. Selection of Initial and Subsequent A ntihyper tensiv e Drug(s) Based on Concurr ent Disease \\nStates \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 2 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 1}), Document(page_content='COPYlisinopril/HC TZ Prinzide/\\nZestoretic 10 mg/\\n12.5 mg \\ndaily 20 mg/12.5 mg daily 20 mg/25 \\nmg daily $4-5 $45 all \\nfosinopril/HC TZ Monopril \\nHCT  10 mg/12.5 mg daily 20 mg/\\n12.5 mg \\ndaily $38 all $42 \\nquinapril/HC TZ Accur etic 10 mg/\\n12.5 mg \\ndaily 20 mg/12.5 mg daily 20 mg/25 \\nmg daily $23 all $79-96 \\nAngiotensin Recept or Block ers \\ntelmisar tan Micar dis  40 mg daily 80 mg \\ndaily $116 all $145 all \\nolmesar tan Benicar  20 mg daily 40 mg \\ndaily n/a $115-160 \\nvalsar tan Diovan 80 mg \\ndaily 160 mg daily 320 mg \\ndaily n/a $127-136 \\nirbesar tan Avapro  150 mg daily 300 mg \\ndaily $12-15 $92-111 \\ncandesar tan Atacand 8 mg \\ndaily 16 mg daily 32 mg \\ndaily $86-107 $95-128 \\neprosar tan Teveten 50 mg \\ndaily 400 mg daily 600 mg \\ndaily $98 $125 \\nlosar tan Cozaar  100 mg daily 50 mg BID $6-12 $113-156 \\nazilsar tan Edarbi  40 mg daily 80 mg \\ndaily n/a $132 \\nAngiotensin Recept or Block er / Diur etic Combinations \\nvalsar tan/HC TZ Diovan \\nHCT 40 mg/\\n12.5 mg \\ndaily 80 mg/12.5 mg daily 160 mg/\\n12.5 mg \\ndaily $16 all $120-142 \\ntelmisar tan/HC TZ Micar dis \\nHCC  80 mg/12.5 mg daily 80 mg/25 \\nmg daily n/a $145 all \\ncandesar tan/HC TZ Atacand \\nHCT  16 mg/12.5 mg daily 32 mg/\\n12.5 mg \\ndaily $60-63 $125 all \\nlosar tan/HC TZ Hyzaar  50 mg/12.5 mg daily 100 mg/\\n25 mg \\ndaily $6-8 $92-118 \\nolmesar tan/HC TZ Benicar \\nHCT 20 mg/\\n12.5 mg \\ndaily 40 mg/12.5 mg daily 40 mg/25 \\nmg daily n/a $160 \\nAmbulatory Adult Hypertension Guideline. Retrieved 07/2023. Official copy at http://michmed-public.policystat.com/policy/\\n8093105/. Copyright © 2023 Michigan Medicine PublicPage 8 of 30', metadata={'source': './mm_htn_guidelines.pdf', 'page': 7})]\n"
     ]
    }
   ],
   "source": [
    "query = \"what is the cheapest bp drug avail?\"\n",
    "qa_doc(query, docsearch)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "ConversationalRetrievalChain(memory=ConversationBufferMemory(chat_memory=ChatMessageHistory(messages=[]), output_key=None, input_key=None, return_messages=True, human_prefix='Human', ai_prefix='AI', memory_key='chat_history'), callbacks=None, callback_manager=None, verbose=False, tags=None, metadata=None, combine_docs_chain=StuffDocumentsChain(memory=None, callbacks=None, callback_manager=None, verbose=False, tags=None, metadata=None, input_key='input_documents', output_key='output_text', llm_chain=LLMChain(memory=None, callbacks=None, callback_manager=None, verbose=False, tags=None, metadata=None, prompt=ChatPromptTemplate(input_variables=['context', 'question'], output_parser=None, partial_variables={}, messages=[SystemMessagePromptTemplate(prompt=PromptTemplate(input_variables=['context'], output_parser=None, partial_variables={}, template=\"Use the following pieces of context to answer the users question. \\nIf you don't know the answer, just say that you don't know, don't try to make up an answer.\\n----------------\\n{context}\", template_format='f-string', validate_template=True), additional_kwargs={}), HumanMessagePromptTemplate(prompt=PromptTemplate(input_variables=['question'], output_parser=None, partial_variables={}, template='{question}', template_format='f-string', validate_template=True), additional_kwargs={})]), llm=ChatOpenAI(cache=None, verbose=False, callbacks=None, callback_manager=None, tags=None, metadata=None, client=<class 'openai.api_resources.chat_completion.ChatCompletion'>, model_name='gpt-3.5-turbo', temperature=0.0, model_kwargs={}, openai_api_key='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', openai_api_base='', openai_organization='', openai_proxy='', request_timeout=None, max_retries=6, streaming=False, n=1, max_tokens=None, tiktoken_model_name=None), output_key='text', output_parser=NoOpOutputParser(), return_final_only=True, llm_kwargs={}), document_prompt=PromptTemplate(input_variables=['page_content'], output_parser=None, partial_variables={}, template='{page_content}', template_format='f-string', validate_template=True), document_variable_name='context', document_separator='\\n\\n'), question_generator=LLMChain(memory=None, callbacks=None, callback_manager=None, verbose=False, tags=None, metadata=None, prompt=PromptTemplate(input_variables=['chat_history', 'question'], output_parser=None, partial_variables={}, template='Given the following conversation and a follow up question, rephrase the follow up question to be a standalone question, in its original language.\\n\\nChat History:\\n{chat_history}\\nFollow Up Input: {question}\\nStandalone question:', template_format='f-string', validate_template=True), llm=ChatOpenAI(cache=None, verbose=False, callbacks=None, callback_manager=None, tags=None, metadata=None, client=<class 'openai.api_resources.chat_completion.ChatCompletion'>, model_name='gpt-3.5-turbo', temperature=0.0, model_kwargs={}, openai_api_key='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', openai_api_base='', openai_organization='', openai_proxy='', request_timeout=None, max_retries=6, streaming=False, n=1, max_tokens=None, tiktoken_model_name=None), output_key='text', output_parser=NoOpOutputParser(), return_final_only=True, llm_kwargs={}), output_key='answer', rephrase_question=True, return_source_documents=False, return_generated_question=False, get_chat_history=None, retriever=VectorStoreRetriever(tags=None, metadata=None, vectorstore=<langchain.vectorstores.chroma.Chroma object at 0x127845550>, search_type='similarity', search_kwargs={}), max_tokens_limit=None)"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# initialize chat\n",
    "from langchain.chains import ConversationalRetrievalChain\n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "\n",
    "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo\", temperature=0)\n",
    "memory = ConversationBufferMemory(memory_key=\"chat_history\", return_messages=True)\n",
    "conversation = ConversationalRetrievalChain.from_llm(\n",
    "    llm, \n",
    "    retriever=vectordb.as_retriever(), \n",
    "    memory=memory,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Based on the provided information, the treatment choice for pregnant women with a blood pressure of 150/110 would typically involve the use of antihypertensive medication. The specific medication would depend on the individual's medical history and any other concurrent conditions. However, it is important to note that the management of hypertension during pregnancy should be done by a physician experienced in managing these conditions. They will consider the fetal well-being and choose the most appropriate medication. It is recommended that women considering pregnancy and who require treatment for hypertension should be on antihypertensive medication ideally three to six months prior to conception. ACE inhibitors, ARBs, and renin inhibitors are contraindicated in pregnancy.\n",
      "The usual dose range for enalapril is 2.5 mg daily to 10 mg daily. The cost for a 30-day supply of enalapril ranges from $7 to $11.\n",
      "Before starting treatment for hypertension, the following tests are recommended:\n",
      "\n",
      "1. Cardiovascular review of systems, including known duration of hypertension.\n",
      "2. Symptoms or previous personal/family history that helps to identify secondary hypertension.\n",
      "3. Presence or absence of other cardiovascular risk factors.\n",
      "4. Psychosocial and environmental factors that may influence blood pressure control.\n",
      "5. Medications being taken.\n",
      "6. Two or more blood pressure measurements separated by 2 minutes with the patient either supine or seated.\n",
      "7. Verification in the contralateral arm.\n",
      "8. Body mass index (BMI), calculated by weight (kg)/[height (m)]2 (possibly waist circumference).\n",
      "9. Funduscopic examination for arteriolar narrowing, nicking, hemorrhages, exudates, etc.\n",
      "10. Neck examination for carotid bruits, distended veins, or enlarged thyroid.\n",
      "11. Heart/lung examination.\n",
      "12. Abdominal examination for enlarged kidneys, masses, distended bladder, renal bruits, aortic aneurysm.\n",
      "13. Extremity examination for pedal pulses and edema.\n",
      "14. Neurological assessment, particularly for signs of cerebrovascular disease.\n",
      "15. Potassium.\n",
      "16. Urinalysis.\n",
      "17. Blood glucose.\n",
      "18. Lipid panel.\n",
      "19. Creatinine.\n",
      "20. EKG.\n",
      "21. Calcium.\n",
      "22. Hematocrit.\n",
      "23. Chronic or acute kidney disease physical examination.\n",
      "24. Other tests and referrals may be considered if secondary hypertension or complicated hypertension is suspected.\n",
      "\n",
      "Please note that this information is based on expert opinion and may vary depending on individual patient factors. It is always best to consult with a healthcare professional for personalized recommendations.\n"
     ]
    }
   ],
   "source": [
    "# chat\n",
    "chat_history = []\n",
    "def qa_doc(query)\n",
    "    # user_input = input(\"> \")\n",
    "    ai_response = conversation({\n",
    "        \"question\": query,\n",
    "        \"chat_history\": chat_history\n",
    "    })\n",
    "    print(ai_response['answer'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[]\n",
      "The target blood pressure for a patient with diabetes is a systolic blood pressure of less than 140 mmHg and a diastolic blood pressure of less than 90 mmHg.\n"
     ]
    }
   ],
   "source": [
    "query1 = \"what is the target bp for a patient with diabetes\"\n",
    "qa_doc(query1)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "myenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
